Protocol #18-0995, No Longer Enrolling: 6/10/2021
Locations: University of Colorado Hospital
More information available at ClinicalTrials.gov: NCT03446664
Protocol #18-1740, No Longer Enrolling: 8/24/2021
Locations: Anschutz Health and Wellness, Outpatient CTRC, UCD Anschutz Health & Wellness Center, University of Colorado Hospital;
The purpose of this research is to demonstrate a relationship between cortisol measured in hair, cortisol measured in saliva, and the results of self-reported psychological measures (questionnaires).
Protocol #20-0025, No Longer Enrolling: 1/21/2021
Locations: Department Specific Free Standing Clinic;
This study is completed online at your convenience. Participants will complete online surveys (the study takes about 25 minutes to complete).
Protocol #20-1583, No Longer Enrolling: 10/14/2020
Locations: Department Specific Free Standing Clinic;
For more information, please email the research team at alcoholstudy@ucdenver.edu or use the link to fill out the study contact information form: https://redcap.link/TrAIL_Lab For participating in the research study, you will be paid up to a total of $595.00. Payments will be pro-rated if you don't complete all parts of the study. The primary objective of this study is to evaluate the effects of ASP8062, 25 mg once a day and matched placebo, on alcohol cue-elicited alcohol craving during a human laboratory paradigm after 2 weeks of daily dosing among subjects with moderate to severe alcohol use disorder (AUD).
Protocol #21-4460, No Longer Enrolling: 4/27/2022
Locations: Department Specific Free Standing Clinic, Outpatient CTRC, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT05096117
Protocol #15-1356, No Longer Enrolling: 10/1/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02483988
Protocol #17-0054, No Longer Enrolling: 3/11/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03012776
Protocol #17-0687, No Longer Enrolling: 4/14/2022
Locations: University of Colorado Hospital;
Protocol #17-0371, No Longer Enrolling: 1/8/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03122899
Protocol #17-1013, No Longer Enrolling: 8/25/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03177473
This is a prospective, multi-center registry of patients treated in accordance with the cleared indications for the Smart, Penumbra Coil 400, and the Penumbra Occlusion Device. Data for each patient are collected in accordance with the standard of care at each participating hospital through one-year follow-up.
Protocol #17-2122, No Longer Enrolling: 7/17/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02729740
The Agili-C™ scaffold is indicated for the treatment of an ICRS grade III or above knee-joint surface lesion(s), with a total treatable area of 1-7cm2 and without severe osteoarthritis (Kellgren-Lawrence grade 0-3)
Protocol #18-2105, No Longer Enrolling: 1/3/2020
Locations: Boulder Sports Clinic, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03299959
Protocol #18-0073, No Longer Enrolling: 1/15/2020
Locations: Childrens Hospital Colorado;
1. To assess the safety and tolerability of QPI-1007 intravitreal (IVT) injections in subjects with recent-onset NAION 2. To determine the effect on visual function of QPI-1007 IVT injections in subjects with recent-onset NAION
Protocol #15-1194, No Longer Enrolling: 11/20/2019
Locations: University of Colorado Hospital;
To assess the safety and efficacy of long-term dosing with patisiran in transthyretin-mediated amyloidosis (ATTR) patients with familial amyloidotic polyneuropathy (FAP).
Protocol #15-1259, No Longer Enrolling: 4/25/2020
Locations: University of Colorado Hospital;
To assess the safety, tolerability and efficacy of Accordion Pill carbidopa/levodopa (AP-CD/LD) compared to Immediate Release carbidopa/levodopa (IR CD/LD) in fluctuating PD patients
Protocol #15-2350, No Longer Enrolling: 10/1/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02605434
To evaluate the safety and tolerability of APL-130277 in patients with Parkinson's disease (PD) over a 24 week period
Protocol #16-0684, No Longer Enrolling: 1/29/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02542696
To create a longitudinal collections of samples and data from: 1. Subjects with clinically-defined or highly suspicious for NMO or NMOSD; 2. Affected or unaffected relatives of subjects with clinically defined NMO or NMOSD; 3. Subjects with autoimmune diseases other NMO or NMOSD, such as multiple sclerosis, myasthenia gravis, Graves' disease, lupus, etc. 4. Healthy subjects
Protocol #13-3181, No Longer Enrolling: 3/5/2022
Locations: University of Colorado Hospital;
To compare the efficacy of MEDI-551 versus placebo in reducing the risk of an NMO/NMOSD attack in subjects with NMO/NMOSD.
Protocol #14-0926, No Longer Enrolling: 4/25/2020
Locations: University of Colorado Hospital;
To calculate annual SAE rate over time in patients treated with RNS System
Protocol #15-1458, No Longer Enrolling: 11/2/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02403843
To determine whether oral inosine dosed to moderately elevate serum urate (from !U5.7 mg/dL to 7.1-8.0 mg/dL) over 2 years slows clinical decline in early PD.
Protocol #15-2328, No Longer Enrolling: 11/14/2019
Locations: University of Colorado Hospital;
To assess the efficacy of IV administered natalizumab, monthly for 1 year, in preventing relapses during the postpartum period.
Protocol #16-0156, No Longer Enrolling: 3/17/2022
Locations: University of Colorado Hospital;
1. To evaluate the device?s ability to record wireless EEG from patients in the long-term EEG monitoring unit 2. To compare wireless EEG in these recordings to standard-of-care wired EEG
Protocol #15-0449, No Longer Enrolling: 8/10/2021
Locations: University of Colorado Hospital;
Protocol #13-0388, No Longer Enrolling: 1/29/2022
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT01838174
To assess the long-term safety of apomorphine continuous infusion in advanced Parkinson?s disease (PD) patients who are unable to achieve adequate motor control despite optimal treatment with noninvasive therapy.
Protocol #15-1274, No Longer Enrolling: 4/25/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02339064
To demonstrate the efficacy of BAF312 relative to placebo in delaying the time to 3-month confirmed disability progression in patients with SPMS as measured by EDSS.
Protocol #13-2286, No Longer Enrolling: 4/15/2020
Locations: University of Colorado Hospital;
To investigate the efficacy of ocrelizumab compared with placebo in patients with primary progressive multiple sclerosis, as measured by the time to onset of confirmed disability progression over the treatment period, defined as an increase in EDSS that is sustained for at least 12 weeks, based on regularly scheduled visits.
Protocol #11-1327, No Longer Enrolling: 11/12/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT01194570
To assess whether the efficacy of ocrelizumab 600 mg (given as dual infusions of 300 mg on Days 1 and 15 of the first 24-week treatment cycle and as a single infusion of 600 mg on Day 1 of each 24-week treatment cycle thereafter) intravenously every 24 weeks is superior to Rebif? as measured by the annualized protocol-defined relapse rate by two years (96 weeks) in patients with relapsing multiple sclerosis.
Protocol #11-1850, No Longer Enrolling: 11/12/2019
Locations: University of Colorado Hospital;
To demonstrate the superiority of MD1003, 300 mg/day, over placebo to clinically improve patients with progressive multiple sclerosis (MS).
Protocol #16-1727, No Longer Enrolling: 4/25/2020
Locations: University of Colorado Hospital;
Protocol #17-0089, No Longer Enrolling: 11/6/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03107052
Protocol #16-1443, No Longer Enrolling: 6/10/2021
Locations: University of Colorado Hospital;
Protocol #17-0207, No Longer Enrolling: 12/10/2019
Locations: University of Colorado Hospital;
Protocol #10-1311, No Longer Enrolling: 7/30/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT01798563
Protocol #11-0647, No Longer Enrolling: 5/10/2021
Locations: University of Colorado Hospital;
Protocol #17-0679, No Longer Enrolling: 10/9/2020
Locations: University of Colorado Hospital;
Protocol #16-0017, No Longer Enrolling: 5/10/2021
Locations: University of Colorado Hospital;
Protocol #16-0644, No Longer Enrolling: 11/14/2019
Locations: University of Colorado Hospital;
Protocol #16-1354, No Longer Enrolling: 12/12/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02980042
Protocol #17-1170, No Longer Enrolling: 6/27/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03277248
Protocol #17-1335, No Longer Enrolling: 10/1/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03196375
Protocol #15-2114, No Longer Enrolling: 5/20/2021
Locations: Memorial Hospital Central, University of Colorado Hospital;
Protocol #17-1396, No Longer Enrolling: 10/1/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02728752
Protocol #17-1322, No Longer Enrolling: 10/12/2021
Locations: Colorado Research Center, Department Specific Free Standing Clinic;
Protocol #17-1751, No Longer Enrolling: 9/25/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02878798
Protocol #17-1825, No Longer Enrolling: 2/22/2020
Locations: University of Colorado Hospital;
Protocol #17-1854, No Longer Enrolling: 11/19/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02753530
Protocol #17-1532, No Longer Enrolling: 10/20/2021
Locations: Outpatient CTRC, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03318523
The ARAMIS registry is designed to provide important and timely insight into the management of acute stroke patients who are on novel oral anticoagulant in community practice
Protocol #17-6111, No Longer Enrolling: 2/18/2020
Locations: Medical Center of the Rockies, Poudre Valley Hospital;
More information available at ClinicalTrials.gov: NCT02478177
Protocol #17-1816, No Longer Enrolling: 6/20/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02644668
The primary objective of the study is to determine, in a randomized, placebo controlled trial, the efficacy of a single intravenous (IV) infusion of unrelated donor UCB for improving functional outcomes in patients with ischemic stroke. The secondary objectives are as follows: 1.To describe the safety and tolerability of a single IV infusion of unrelated donor UCB in patients with ischemic stroke 2.To evaluate the efficacy of a single IV infusion of unrelated donor UCB for improvement of neurological symptoms following ischemic stroke 3.To evaluate the efficacy of a single IV infusion of unrelated donor UCB for improvement in quality of life and emotional and cognitive status in patients with ischemic stroke
Protocol #17-2136, No Longer Enrolling: 5/20/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03004976
Protocol #17-2165, No Longer Enrolling: 5/11/2021
Locations: Lone Tree Medical Center, UCHealth Internal Medical Clinic - Lowry, University of Colorado Hospital;
Protocol #17-2318, No Longer Enrolling: 11/20/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03582137
Protocol #15-0657, No Longer Enrolling: 2/27/2020
Locations: University of Colorado Hospital;
Protocol #16-0120, No Longer Enrolling: 11/12/2019
Locations: University of Colorado Hospital;
Protocol #16-2179, No Longer Enrolling: 5/11/2021
Locations: University of Colorado Hospital;
Protocol #17-0087, No Longer Enrolling: 11/6/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02945046
Protocol #17-0088, No Longer Enrolling: 10/1/2019
Locations: University of Colorado Hospital;
Protocol #18-0113, No Longer Enrolling: 3/12/2020
Locations: Anschutz Health and Wellness, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03407378
Protocol #18-0020, No Longer Enrolling: 5/4/2022
Locations: University of Colorado Hospital;
Protocol #17-2111, No Longer Enrolling: 4/15/2020
Locations: Childrens Hospital Colorado;
1).Optimize tACS parameters for duration, intensity and frequencies via utilization of EEG data recorded during tACS stimulation. 2)Determine whether recording artifacts introduced by tACS can confidently be removed from EEG signals. 3). Determine effects of tACS delivered with nested frequencies(multi-frequency signal) vs single frequency tACS, with regard to intrinsic EEG signal, for modulation of SWA coherence and power, as recorded in our overnight EEG sleep data. 4). Determine the cumulative effects of tACS delivered in multiple, consecutive nights on underlying EEG signals, sleep architecture, sleep quality and cognitive function among patients with MCI. 5). Determine if tACS is a viable treatment for disturbances of sleep and cognitive performance among patients with MCI. 6). Generate pilot data and manuscripts to support applications for larger randomized placebo-controlled clinical trials.
Protocol #16-1875, No Longer Enrolling: 5/5/2021
Locations: Colorado Research Center, Department Specific Free Standing Clinic, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03112902
Protocol #15-2388, No Longer Enrolling: 11/13/2020
Locations: University of Colorado Hospital;
Protocol #17-2334, No Longer Enrolling: 10/14/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03309332
Protocol #18-0375, No Longer Enrolling: 12/20/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03436199
Protocol #18-0482, No Longer Enrolling: 4/25/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03222973
Protocol #16-2178, No Longer Enrolling: 10/1/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02907177
Protocol #08-0613, No Longer Enrolling: 10/1/2019
Locations: University of Colorado Hospital;
Protocol #15-2351, No Longer Enrolling: 11/6/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02615873
Protocol #18-0787, No Longer Enrolling: 11/22/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02927080
Study is double blind and placebo controlled.
Protocol #18-0829, No Longer Enrolling: 5/10/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03562494
Protocol #16-0121, No Longer Enrolling: 1/6/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02739542
Protocol #17-0599, No Longer Enrolling: 10/28/2020
Locations: University of Colorado Hospital;
Protocol #18-0996, No Longer Enrolling: 11/6/2019
Locations: Brain Imaging Center (BIC), Colorado Research Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03124459
Protocol #18-0995, No Longer Enrolling: 6/10/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03446664
Protocol #18-1262, No Longer Enrolling: 11/6/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03606460
Protocol #18-0997, No Longer Enrolling: 4/25/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02534844
Protocol #18-1592, No Longer Enrolling: 11/6/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03560739
Protocol #18-1336, No Longer Enrolling: 3/3/2022
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02796261
Protocol #17-2029, No Longer Enrolling: 11/14/2019
Locations: University of Colorado Hospital;
Protocol #18-1875, No Longer Enrolling: 12/4/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03701399
Protocol #18-2047, No Longer Enrolling: 5/10/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03670953
Protocol #18-1768, No Longer Enrolling: 5/11/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02795897
Protocol #18-2059, No Longer Enrolling: 11/22/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03650114
Protocol #18-2152, No Longer Enrolling: 4/25/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03737812
Protocol #18-2451, No Longer Enrolling: 4/25/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03737851
Protocol #18-2341, No Longer Enrolling: 4/25/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03772587
Protocol #18-2423, No Longer Enrolling: 2/29/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03710707
Protocol #18-2237, No Longer Enrolling: 11/22/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03759379
Protocol #18-2536, No Longer Enrolling: 11/6/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03669588
Protocol #18-2535, No Longer Enrolling: 11/22/2019
Locations: Brain Imaging Center (BIC), Colorado Research Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03689972
Protocol #19-0363, No Longer Enrolling: 4/25/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03567057
Protocol #19-0393, No Longer Enrolling: 8/11/2021
Locations: Brain Imaging Center (BIC), University of Colorado Hospital;
Protocol #19-0025, No Longer Enrolling: 2/21/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03781167
Protocol #19-0478, No Longer Enrolling: 7/7/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03922711
Protocol #19-0414, No Longer Enrolling: 5/10/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03750552
Protocol #19-0212, No Longer Enrolling: 5/5/2021
Locations: University of Colorado Hospital;
Protocol #19-0520, No Longer Enrolling: 5/10/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03829657
Protocol #19-0150, No Longer Enrolling: 5/11/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03896295
Protocol #19-0720, No Longer Enrolling: 11/14/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03943290
Protocol #19-0772, No Longer Enrolling: 5/11/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03920293
Protocol #19-1251, No Longer Enrolling: 5/5/2021
Locations: Brain Imaging Center (BIC), Department Specific Free Standing Clinic;
Protocol #19-1597, No Longer Enrolling: 6/24/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03971422
Protocol #19-1925, No Longer Enrolling: 9/14/2021
Locations: University of Colorado Hospital;
Protocol #19-1396, No Longer Enrolling: 2/7/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03478982
Protocol #19-1599, No Longer Enrolling: 3/28/2020
Locations: Brain Imaging Center (BIC), University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04001517
Protocol #19-1620, No Longer Enrolling: 4/6/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03796962
Protocol #19-1929, No Longer Enrolling: 5/13/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04124965
Protocol #19-1040, No Longer Enrolling: 6/8/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03972306
Protocol #19-1461, No Longer Enrolling: 3/17/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03877510
Protocol #19-1455, No Longer Enrolling: 6/10/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02549170
Protocol #19-0865, No Longer Enrolling: 5/10/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03681015
Protocol #19-2471, No Longer Enrolling: 3/30/2022
Locations: Outpatient CTRC, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04154072
Protocol #19-2897, No Longer Enrolling: 4/17/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04380142
Protocol #19-1598, No Longer Enrolling: 5/11/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04049097
Protocol #19-1840, No Longer Enrolling: 6/10/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04102579
Protocol #19-1505, No Longer Enrolling: 3/28/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04152083
Protocol #19-2377, No Longer Enrolling: 5/11/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04577404
Protocol #19-1980, No Longer Enrolling: 1/25/2022
Locations: Brain Imaging Center (BIC), Outpatient CTRC, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03963375
Protocol #20-0729, No Longer Enrolling: 5/5/2021
Locations: Brain Imaging Center (BIC), University of Colorado Hospital;
Protocol #20-0571, No Longer Enrolling: 5/7/2021
Locations: Brain Imaging Center (BIC), University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04241068
Protocol #20-0404, No Longer Enrolling: 5/11/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04248465
Protocol #19-2503, No Longer Enrolling: 5/5/2021
Locations: University of Colorado Hospital;
Protocol #20-0127, No Longer Enrolling: 3/17/2022
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03489278
Protocol #19-1566, No Longer Enrolling: 5/4/2022
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03884231
Protocol #20-0609, No Longer Enrolling: 11/13/2021
Locations: Outpatient CTRC, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04159805
NTX-001 is a single use surgical product intended for use in conjunction with standard suture neurorrhaphy of a severed nerves in patients between 16 and 65 years of age.
Protocol #20-1997, No Longer Enrolling: 10/9/2021
Locations: Denver Health and Hospital Authority, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04572906
Protocol #20-2005, No Longer Enrolling: 3/17/2022
Locations: CTRC Inpatient, Outpatient CTRC, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04579666
Protocol #21-2881, No Longer Enrolling: 1/14/2022
Locations: University of Colorado Hospital;
Protocol #20-2740, No Longer Enrolling: 6/24/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04650854
Protocol #21-2663, No Longer Enrolling: 3/31/2022
Locations: Brain Imaging Center (BIC), University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04544449
Protocol #21-2746, No Longer Enrolling: 9/16/2021
Locations: Outpatient CTRC, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04115293
Protocol #21-4249, No Longer Enrolling: 3/8/2022
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT05021536
This is a clinical trial of cisplatin that will be administered by IV which is standard of care and radiation therapy that will be administered standard of care.
Protocol #13-2078, No Longer Enrolling: 3/10/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT01220583
This is a clinical trial of radiation that will be administered after a lumpectomy, to the breast and lymph nodes or mastectomy, to the area where the breast used to be and lymph nodes. This is done to see if giving radiation as described above will help women live longer.
Protocol #13-2454, No Longer Enrolling: 12/31/2020
Locations: Greeley Campus, Harmony Campus, Lone Tree Medical Center, Medical Center of the Rockies, Memorial Hospital Central, Memorial Hospital North, Poudre Valley Hospital, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT01872975
This is a clinical trial of PT-112 that will be administered injection which is investigational.
Protocol #14-0151, No Longer Enrolling: 3/11/2022
Locations: Outpatient CTRC, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02266745
This is a clinical trial of investigational drug POL-103A, which will be administered by injections (shots).
Protocol #12-1076, No Longer Enrolling: 8/20/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT01546571
Protocol #14-1764, No Longer Enrolling: 1/29/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02372539
This is a clinical trial of standard of care and SBRT that will be administered by radiotherapy and is investigational.
Protocol #15-0136, No Longer Enrolling: 10/1/2019
Locations: Greeley Hospital, Harmony Campus, Medical Center of the Rockies, Memorial Hospital Central, Poudre Valley Hospital, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02364557
Protocol #15-0150, No Longer Enrolling: 6/8/2021
Locations: Dana Farber Cancer Institute, Lone Tree Medical Center, Mayo Clinic, Arizona, New York University, University of Arizona Cancer Center, University of Colorado Hospital, University of Kansas Cancer Center;
More information available at ClinicalTrials.gov: NCT02723331
Protocol #15-0801, No Longer Enrolling: 9/4/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02091141
Protocol #15-1618, No Longer Enrolling: 5/22/2020
;
More information available at ClinicalTrials.gov: NCT02306161
Protocol #15-1574, No Longer Enrolling: 1/8/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02568267
Protocol #15-1825, No Longer Enrolling: 6/29/2021
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02601937
Protocol #15-1135, No Longer Enrolling: 3/19/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02719691
Protocol #15-1894, No Longer Enrolling: 4/1/2022
Locations: Lone Tree Medical Center, Memorial Hospital Central, Memorial Hospital North, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02468024
Protocol #15-1932, No Longer Enrolling: 2/26/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02393690
Protocol #15-1995, No Longer Enrolling: 11/27/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02659020
Protocol #15-2301, No Longer Enrolling: 11/8/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02628067
1. To determine the safety profile of orally administered AP32788 2. To identify the RP2D, dose-limiting toxicities (DLTs), and the maximum tolerated dose (MTD) of AP32788 3 .To determine the pharmacokinetic (PK) profile of AP32788 and its active metabolites, AP32960 and AP32914 4. To evaluate the anti-tumor activity of AP32788 in NSCLC patients with EGFR or HER2 mutations 5. To explore associations between tumor and plasma biomarkers and AP32788 efficacy and safety
Protocol #16-0208, No Longer Enrolling: 2/14/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02716116
Protocol #15-1921, No Longer Enrolling: 9/14/2021
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT01979536
A comparison of exercise versus no exercise in men with Metastatic Castrate-Resistant Prostate Cancer.
Protocol #16-0227, No Longer Enrolling: 10/1/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02730338
Protocol #16-0207, No Longer Enrolling: 7/31/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02671435
Protocol #16-0493, No Longer Enrolling: 8/13/2021
Locations: Lone Tree Medical Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02466971
Protocol #16-0506, No Longer Enrolling: 9/30/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02706626
Protocol #16-0628, No Longer Enrolling: 7/10/2020
Locations: Lone Tree Medical Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02702492
Protocol #16-0709, No Longer Enrolling: 4/20/2022
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02521493
Protocol #16-0708, No Longer Enrolling: 10/6/2020
Locations: Greeley Campus, Harmony Campus, Highlands Ranch Hospital, Medical Center of the Rockies, Memorial Hospital Central, Memorial Hospital North, Poudre Valley Hospital, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02502266
Protocol #16-0749, No Longer Enrolling: 5/12/2022
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02650401
Protocol #16-1057, No Longer Enrolling: 7/15/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT01827384
Protocol #16-1042, No Longer Enrolling: 9/9/2021
Locations: Highlands Ranch Hospital, Lone Tree Medical Center, Memorial Sloan Kettering Cancer Center, University of Colorado Hospital, West Cancer Center;
More information available at ClinicalTrials.gov: NCT02955394
Protocol #16-1217, No Longer Enrolling: 10/27/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02498951
Protocol #16-1225, No Longer Enrolling: 11/12/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03030287
Protocol #16-1241, No Longer Enrolling: 10/4/2019
Locations: Greeley Hospital, Harmony Campus, Medical Center of the Rockies, Memorial Hospital Central, Memorial Hospital North, Poudre Valley Hospital, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02595944
Protocol #16-1205, No Longer Enrolling: 12/17/2020
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02285439
To establish safety and efficacy of Niraparib in patients with targeted DNA- repair anomalies
Protocol #16-1470, No Longer Enrolling: 4/9/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02854436
A rollover study to continue to document patients previously enrolled to an enzalutamide study
Protocol #16-1640, No Longer Enrolling: 5/28/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02960022
Protocol #16-1825, No Longer Enrolling: 8/7/2020
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02644460
A comparison of Gem/Cis +/- VX-970
Protocol #16-1951, No Longer Enrolling: 12/31/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02567409
Atezolizumab vs. placebo as adjuvant therapy post nephrectomy
Protocol #16-1420, No Longer Enrolling: 10/28/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03024996
Protocol #15-1936, No Longer Enrolling: 3/17/2022
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02323880
Protocol #16-2269, No Longer Enrolling: 2/9/2021
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02979522
Protocol #16-2025, No Longer Enrolling: 9/23/2020
Locations: Lone Tree Medical Center, University of California San Francisco, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03088930
Protocol #16-2230, No Longer Enrolling: 3/31/2020
Locations: Dana Farber Cancer Institute, MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, The Ohio State University Comprehensive Cancer Center, UCLA, Jonsson Cancer Center, University of Colorado Hospital, University of Michigan Comprehensive Cancer Center;
More information available at ClinicalTrials.gov: NCT02973997
To assess the efficacy of Prmbrolizumab plus Cabozantinib in patients with metastatic renal cell carcinoma
Protocol #16-2300, No Longer Enrolling: 12/19/2020
Locations: Greeley Campus, Harmony Campus, Highlands Ranch Hospital, Lone Tree Medical Center, Medical Center of the Rockies, Memorial Hospital Central, Memorial Hospital North, Poudre Valley Hospital, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03149822
Protocol #16-2449, No Longer Enrolling: 4/27/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02935634
Protocol #16-2248, No Longer Enrolling: 2/24/2021
Locations: Lone Tree Medical Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03013218
Protocol #17-0029, No Longer Enrolling: 10/1/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03119467
Protocol #16-2696, No Longer Enrolling: 12/24/2020
Locations: Lone Tree Medical Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03132636
Protocol #16-2407, No Longer Enrolling: 4/11/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03069469
Protocol #17-0074, No Longer Enrolling: 7/2/2021
Locations: Lone Tree Medical Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03323398
Protocol #17-0280, No Longer Enrolling: 10/23/2020
Locations: Greeley Campus, Harmony Campus, Medical Center of the Rockies, Memorial Hospital Central, Memorial Hospital North, Poudre Valley Hospital, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02834013
Protocol #17-7836, No Longer Enrolling: 12/17/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02516696
A comparison of Nivolumab vs no Nivolumab prior to nephrectomy.
Protocol #17-0406, No Longer Enrolling: 11/25/2020
Locations: Greeley Campus, Harmony Campus, Lone Tree Medical Center, Medical Center of the Rockies, Memorial Hospital Central, Memorial Hospital North, Poudre Valley Hospital, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03055013
Protocol #17-0402, No Longer Enrolling: 9/11/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03474640
Protocol #17-0512, No Longer Enrolling: 3/2/2022
Locations: Lone Tree Medical Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02892123
Protocol #17-0491, No Longer Enrolling: 2/7/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02983045
Protocol #17-0614, No Longer Enrolling: 1/3/2020
Locations: Greeley Hospital, Harmony Campus, Medical Center of the Rockies, Memorial Hospital Central, Poudre Valley Hospital, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02893930
Protocol #17-0173, No Longer Enrolling: 10/1/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03135262
Protocol #17-0401, No Longer Enrolling: 7/10/2021
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02927769
Protocol #17-0828, No Longer Enrolling: 5/14/2020
Locations: Greeley Campus, Harmony Campus, Medical Center of the Rockies, Poudre Valley Hospital;
More information available at ClinicalTrials.gov: NCT03137771
Protocol #17-0767, No Longer Enrolling: 10/25/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02817633
Protocol #17-0948, No Longer Enrolling: 5/19/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02964013
Protocol #17-0996, No Longer Enrolling: 12/29/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03070392
A comparison of Nivolumab + cabozantinib vs Nivolumab + Ipilimumab + Cabozantinib vs Sunitinb in patients with kidney cancer
Protocol #17-1121, No Longer Enrolling: 10/17/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03141177
Protocol #17-0754, No Longer Enrolling: 1/16/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03318016
Protocol #17-1167, No Longer Enrolling: 2/8/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03184870
Protocol #17-0991, No Longer Enrolling: 3/2/2022
Locations: Lone Tree Medical Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03289962
Protocol #17-1045, No Longer Enrolling: 10/27/2020
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02867592
Protocol #17-7821, No Longer Enrolling: 2/6/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03466294
Protocol #17-0900, No Longer Enrolling: 3/28/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03218683
Protocol #17-1333, No Longer Enrolling: 10/8/2020
Locations: Lone Tree Medical Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03325634
Protocol #15-1466, No Longer Enrolling: 3/18/2022
Locations: Denver Health and Hospital Authority, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02135419
Protocol #17-6155, No Longer Enrolling: 7/8/2021
Locations: Memorial Hospital Central;
More information available at ClinicalTrials.gov: NCT02953704
Protocol #17-0694, No Longer Enrolling: 11/14/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03253575
Protocol #17-1376, No Longer Enrolling: 8/19/2021
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02975882
Protocol #17-1452, No Longer Enrolling: 12/14/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02675439
Protocol #17-1501, No Longer Enrolling: 10/28/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02574455
Protocol #17-1474, No Longer Enrolling: 2/9/2021
Locations: Lone Tree Medical Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02360579
Protocol #17-1021, No Longer Enrolling: 9/16/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03374254
Protocol #16-2575, No Longer Enrolling: 6/23/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04091867
Protocol #17-1790, No Longer Enrolling: 1/8/2021
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT01089101
Protocol #17-1406, No Longer Enrolling: 4/21/2021
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02684058
Protocol #17-1777, No Longer Enrolling: 7/10/2020
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT03263936
Assessment of TAK 228 in metastatic kidney cancer
Protocol #17-0727, No Longer Enrolling: 2/12/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03097328
Protocol #17-0619, No Longer Enrolling: 6/24/2020
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02828358
Protocol #17-1834, No Longer Enrolling: 8/13/2020
Locations: Greeley Campus, Memorial Hospital Central, Memorial Hospital North, Poudre Valley Hospital;
More information available at ClinicalTrials.gov: NCT03033576
Protocol #17-1757, No Longer Enrolling: 6/6/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03381274
Protocol #17-1943, No Longer Enrolling: 7/10/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03359850
Subjects will receive treatment with nivolumab as a 30 minute IV infusion on Day 1 of a treatment cycle every two weeks (14 days). There will be no dose escalations or reductions allowed. Treatment may be delayed for up to a maximum of 2 weeks from the scheduled re-treatment date. Subjects may be dosed no less than 12 days from the previous dose.
Protocol #17-1492, No Longer Enrolling: 11/17/2021
Locations: Rocky Mountain Regional VA Medical Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03347838
Protocol #17-1974, No Longer Enrolling: 12/11/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03393000
Protocol #17-1481, No Longer Enrolling: 8/15/2020
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02703272
Protocol #17-2086, No Longer Enrolling: 2/26/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03144687
Protocol #17-1808, No Longer Enrolling: 1/4/2022
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03037385
Protocol #17-1940, No Longer Enrolling: 12/6/2019
Locations: Rocky Mountain Regional VA Medical Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03409016
Protocol #17-2125, No Longer Enrolling: 8/11/2021
Locations: Greeley Campus, Highlands Ranch Hospital, Medical Center of the Rockies, Memorial Hospital Central, Memorial Hospital North, Poudre Valley Hospital, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03365882
Protocol #17-1778, No Longer Enrolling: 5/13/2022
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03417882
Protocol #17-1845, No Longer Enrolling: 8/27/2020
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT03451825
Protocol #17-2164, No Longer Enrolling: 8/4/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT01968109
Protocol #17-2198, No Longer Enrolling: 7/21/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03345784
Protocol #17-2189, No Longer Enrolling: 3/28/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03336216
Protocol #17-2257, No Longer Enrolling: 11/18/2020
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT01964300
Protocol #17-2450, No Longer Enrolling: 8/21/2020
Locations: Lone Tree Medical Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03425279
A PHASE 1B, OPEN LABEL, MULTI-CENTER TRIAL OF AB-110 IN ADULTS WITH HEMATOLOGIC MALIGNANCIES UNDERGOING CORD BLOOD TRANSPLANTATION To assess the safety of infusing AB-110, cord blood (CB) hematopoietic stem and progenitor cells (HSPCs) with engineered human umbilical vein endothelial cells.
Protocol #17-2078, No Longer Enrolling: 7/15/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03483324
Protocol #17-2381, No Longer Enrolling: 10/9/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02496663
Protocol #17-2226, No Longer Enrolling: 3/19/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03449030
Protocol #17-2451, No Longer Enrolling: 9/4/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02988817
Protocol #18-0031, No Longer Enrolling: 2/5/2022
Locations: Lone Tree Medical Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03446040
Protocol #17-2216, No Longer Enrolling: 3/8/2022
Locations: Memorial Hospital Central, Memorial Hospital North, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03426306
Protocol #18-0033, No Longer Enrolling: 9/11/2020
Locations: Lone Tree Medical Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03369223
Protocol #18-0187, No Longer Enrolling: 10/29/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03409458
Protocol #17-2208, No Longer Enrolling: 2/17/2021
Locations: Lone Tree Medical Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03332797
Protocol #18-0017, No Longer Enrolling: 4/21/2021
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT03323034
Protocol #18-0320, No Longer Enrolling: 6/5/2020
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT03320330
Protocol #17-0466, No Longer Enrolling: 9/29/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03475004
Protocol #18-0154, No Longer Enrolling: 4/25/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03459222
Protocol #18-0247, No Longer Enrolling: 3/25/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03864042
Protocol #16-2322, No Longer Enrolling: 4/15/2021
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02840409
Protocol #17-6238, No Longer Enrolling: 10/1/2019
Locations: Greeley Hospital, Harmony Campus, Medical Center of the Rockies, Poudre Valley Hospital;
More information available at ClinicalTrials.gov: NCT02793583
Protocol #18-0286, No Longer Enrolling: 8/13/2020
Locations: Greeley Campus, Harmony Campus, Lone Tree Medical Center, Long's Peak Hospital, Longs Peak Hospital, Medical Center of the Rockies, Memorial Hospital Central, Poudre Valley Hospital, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03258554
Protocol #18-0504, No Longer Enrolling: 5/13/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03148327
Protocol #18-0167, No Longer Enrolling: 12/23/2020
Locations: Rocky Mountain Regional VA Medical Center;
Protocol #18-0285, No Longer Enrolling: 10/7/2020
Locations: Lone Tree Medical Center, Memorial Hospital Central, Memorial Hospital North, Poudre Valley Hospital, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03367702
Protocol #18-0269, No Longer Enrolling: 11/8/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03465722
Protocol #18-0541, No Longer Enrolling: 4/2/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03509012
A comparison of Neoadjuvant Nivolumab with versus without Urelumab in patients with cisplatin-ineligible bladder cancer
Protocol #18-0760, No Longer Enrolling: 6/2/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02845323
A comparison of Talazoparib plus enzalutamide vs placebo plus enzalutamide
Protocol #18-0884, No Longer Enrolling: 4/9/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03395197
Protocol #18-0627, No Longer Enrolling: 8/17/2021
Locations: Highlands Ranch Hospital, Memorial Hospital Central, Memorial Hospital North, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03414970
Protocol #18-0871, No Longer Enrolling: 10/23/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03611556
Protocol #18-0965, No Longer Enrolling: 4/10/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03637491
A comparison of enzalutamide with and without CPI1205 in patients with metastatic prostate cancer
Protocol #18-0990, No Longer Enrolling: 3/7/2020
Locations: Lone Tree Medical Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03480646
Protocol #18-0606, No Longer Enrolling: 3/3/2021
Locations: Greeley Campus, Harmony Campus, Medical Center of the Rockies, Memorial Hospital Central, Memorial Hospital North, Pikes Peak Regional Hospital, Poudre Valley Hospital, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03635164
Protocol #18-6506, No Longer Enrolling: 12/5/2019
Locations: Memorial Hospital Central, Memorial Hospital North, Pikes Peak Regional Hospital;
More information available at ClinicalTrials.gov: NCT03382912
Protocol #18-1049, No Longer Enrolling: 12/22/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03083873
Protocol #18-1150, No Longer Enrolling: 11/16/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03634982
Protocol #18-1093, No Longer Enrolling: 8/26/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03466320
Protocol #18-0708, No Longer Enrolling: 12/18/2020
Locations: City of Hope Cancer Center, Lone Tree Medical Center, Thomas Jefferson University Hospital Cancer Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03586999
Protocol #18-1199, No Longer Enrolling: 5/4/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03553836
Protocol #18-1100, No Longer Enrolling: 11/10/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03662698
Protocol #18-1203, No Longer Enrolling: 7/28/2020
Locations: Memorial Hospital Central, Memorial Hospital North;
More information available at ClinicalTrials.gov: NCT03087708
Protocol #18-1263, No Longer Enrolling: 2/5/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03744468
Protocol #18-1347, No Longer Enrolling: 4/2/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03563248
Protocol #18-1430, No Longer Enrolling: 10/23/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03662659
Protocol #18-0867, No Longer Enrolling: 4/13/2022
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT03384654
Protocol #18-1431, No Longer Enrolling: 4/16/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03658772
Protocol #18-1477, No Longer Enrolling: 3/4/2020
Locations: Greeley Hospital, Harmony Campus, Longs Peak Hospital, Medical Center of the Rockies, Poudre Valley Hospital, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03217266
Protocol #18-1214, No Longer Enrolling: 10/2/2019
Locations: Greeley Hospital, Harmony Campus, Medical Center of the Rockies, Poudre Valley Hospital;
More information available at ClinicalTrials.gov: NCT03499808
Protocol #18-1216, No Longer Enrolling: 8/28/2021
Locations: Greeley Campus, Harmony Campus, Lone Tree Medical Center, Medical Center of the Rockies, Memorial Hospital Central, Memorial Hospital North, Pikes Peak Regional Hospital, Poudre Valley Hospital, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03233711
Protocol #18-1337, No Longer Enrolling: 2/19/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03522246
Protocol #18-1654, No Longer Enrolling: 1/26/2022
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03126630
Protocol #18-1659, No Longer Enrolling: 6/2/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02729298
Protocol #18-1343, No Longer Enrolling: 10/2/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03635983
Evaluating the addition of apalutamide to radiotherapy for men with recurrent prostate cancer
Protocol #18-1742, No Longer Enrolling: 2/14/2020
Locations: Greeley Hospital, Harmony Campus, Medical Center of the Rockies, Memorial Hospital Central, Memorial Hospital North, Pikes Peak Regional Hospital, Poudre Valley Hospital, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03371719
Protocol #18-1422, No Longer Enrolling: 12/18/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03597282
Protocol #18-1721, No Longer Enrolling: 1/27/2021
Locations: Greeley Campus, Highlands Ranch Hospital, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03616574
Protocol #18-1741, No Longer Enrolling: 10/1/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03666988
Protocol #18-1599, No Longer Enrolling: 6/22/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03599713
Feasibility of the administration of transdermal testosterone alternating with enzalutamide and the effects it has in the treatment of prostate cancer
Protocol #18-0821, No Longer Enrolling: 5/25/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03734653
Protocol #18-1595, No Longer Enrolling: 11/19/2019
Locations: Memorial Hospital Central, Memorial Hospital North;
More information available at ClinicalTrials.gov: NCT02856581
Protocol #18-1869, No Longer Enrolling: 10/1/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03770689
Protocol #18-6061, No Longer Enrolling: 5/8/2021
Locations: Greeley Campus, Harmony Campus, Medical Center of the Rockies;
More information available at ClinicalTrials.gov: NCT03657043
Protocol #18-1983, No Longer Enrolling: 3/21/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03651128
Protocol #18-1933, No Longer Enrolling: 11/25/2020
Locations: Lone Tree Medical Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03330847
A comparison of Provenge versus active surveillance in low risk prostate cancer patients.
Protocol #18-1980, No Longer Enrolling: 10/5/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03686683
Protocol #18-1858, No Longer Enrolling: 7/10/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03785964
Protocol #18-1856, No Longer Enrolling: 12/1/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03673501
Protocol #18-1919, No Longer Enrolling: 1/8/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03690388
Protocol #18-6510, No Longer Enrolling: 9/29/2021
Locations: Memorial Hospital Central, Memorial Hospital North, Pikes Peak Regional Hospital;
More information available at ClinicalTrials.gov: NCT02180711
Protocol #18-2309, No Longer Enrolling: 9/30/2020
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02502708
Evaluate the safety and tolerability of FOR46 at escalating dose levels and administered intravenously (IV) every 21 days in relapsed/refractory multiple myeloma patients. And determine the maximum-tolerated dose and/or the recommended Phase 2 dose (RP2D) of FOR46 administered IV every 21 days in relapsed/refractory multiple myeloma patients.
Protocol #18-2354, No Longer Enrolling: 2/4/2022
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03650491
Protocol #18-6118, No Longer Enrolling: 11/26/2019
Locations: Memorial Hospital Central, Memorial Hospital North, Pikes Peak Regional Hospital;
More information available at ClinicalTrials.gov: NCT03685344
Protocol #18-1816, No Longer Enrolling: 10/2/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03931681
Protocol #18-2198, No Longer Enrolling: 5/6/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03820986
Protocol #18-2293, No Longer Enrolling: 1/31/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03693170
Protocol #18-2219, No Longer Enrolling: 8/28/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03684811
Protocol #18-2382, No Longer Enrolling: 12/11/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT01989585
Protocol #18-2334, No Longer Enrolling: 7/11/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03253679
A comparison of M6620 + Carboplatin versus Docetaxel + Carboplatin in metastatic castrate-resistant prostate cancer
Protocol #18-2398, No Longer Enrolling: 8/7/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03517969
Protocol #18-2488, No Longer Enrolling: 12/16/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03505710
Protocol #18-2466, No Longer Enrolling: 4/10/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03797326
Protocol #18-2487, No Longer Enrolling: 7/1/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03822351
Protocol #16-2621, No Longer Enrolling: 1/6/2021
Locations: Denver Health Medical Center, National Jewish Health, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03016403
Protocol #18-0710, No Longer Enrolling: 10/1/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03802747
Protocol #18-2357, No Longer Enrolling: 4/9/2020
Locations: Lone Tree Medical Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03701334
Protocol #18-2569, No Longer Enrolling: 6/10/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02033616
Protocol #19-0011, No Longer Enrolling: 1/30/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03805841
Protocol #18-6515, No Longer Enrolling: 9/14/2021
Locations: Memorial Hospital Central;
More information available at ClinicalTrials.gov: NCT03750786
Protocol #18-2874, No Longer Enrolling: 1/7/2022
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03891654
Protocol #19-0127, No Longer Enrolling: 7/27/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03456063
Protocol #19-0233, No Longer Enrolling: 4/10/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03726333
Protocol #19-0207, No Longer Enrolling: 11/16/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03601897
A PHASE I, MULTICENTER, OPEN-LABEL PREOPERATIVE, SHORT-TERM WINDOW STUDY OF GDC-9545 IN POSTMENOPAUSAL WOMEN WITH STAGE IIII OPERABLE, ESTROGEN RECEPTORPOSITIVE BREAST CANCER
Protocol #19-0206, No Longer Enrolling: 6/9/2021
Locations: Lone Tree Medical Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03916744
Protocol #19-0326, No Longer Enrolling: 3/25/2020
Locations: Highlands Ranch Hospital, Lone Tree Medical Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03901339
Protocol #19-0232, No Longer Enrolling: 10/9/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03859752
Protocol #19-0172, No Longer Enrolling: 12/2/2021
Locations: Outpatient CTRC, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03815058
Protocol #19-0161, No Longer Enrolling: 4/3/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03911869
Protocol #19-6041, No Longer Enrolling: 9/9/2020
Locations: Greeley Campus, Harmony Campus, Medical Center of the Rockies, Poudre Valley Hospital;
More information available at ClinicalTrials.gov: NCT03778931
A comparison of Pembrolizumab plus Docetaxel versus placebo plus Docetaxel in patients with chemo-naive, metastatic prostate cancer.
Protocol #19-0473, No Longer Enrolling: 5/21/2021
Locations: Highlands Ranch Hospital, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03834506
A double blind comparison of enzalutamide plus pembrolizumab or placebo in patients with metastatic prostate cancer.
Protocol #19-0493, No Longer Enrolling: 5/3/2022
Locations: Highlands Ranch Hospital, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03834493
Protocol #19-0507, No Longer Enrolling: 6/17/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03884101
Protocol #19-0556, No Longer Enrolling: 11/18/2021
Locations: Lone Tree Medical Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04001101
Protocol #19-0702, No Longer Enrolling: 12/21/2019
Locations: University of Colorado Hospital;
Comparison of drink supplements in evaluation of post-operative Bladder cancer patients
Protocol #19-0818, No Longer Enrolling: 10/8/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03757949
Multiparametric MRI in Evaluating Cancer Stage and Helping Treatment Planning in Patients With Prostate cancer
Protocol #19-0819, No Longer Enrolling: 10/17/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03697148
Protocol #19-0554, No Longer Enrolling: 4/20/2022
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04028063
Protocol #19-1151, No Longer Enrolling: 6/12/2020
Locations: Lone Tree Medical Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03738228
Protocol #19-1152, No Longer Enrolling: 5/4/2022
Locations: Greeley Campus, Harmony Campus, Highlands Ranch Hospital, Lone Tree Medical Center, Medical Center of the Rockies, Memorial Hospital Central, Memorial Hospital North, Poudre Valley Hospital, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03199885
Protocol #19-1121, No Longer Enrolling: 10/27/2020
Locations: Greeley Campus, Harmony Campus, Highlands Ranch Hospital, Medical Center of the Rockies, Poudre Valley Hospital, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03793179
Protocol #19-1317, No Longer Enrolling: 7/21/2020
Locations: Greeley Campus, Harmony Campus, Highlands Ranch Hospital, Lone Tree Medical Center, Medical Center of the Rockies, Memorial Hospital Central, Memorial Hospital North, Poudre Valley Hospital, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03845296
Protocol #19-1318, No Longer Enrolling: 11/21/2020
Locations: Greeley Campus, Harmony Campus, Highlands Ranch Hospital, Lone Tree Medical Center, Medical Center of the Rockies, Memorial Hospital Central, Memorial Hospital North, Poudre Valley Hospital, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03971474
Protocol #19-1111, No Longer Enrolling: 12/4/2020
Locations: Childrens Hospital Colorado, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04066218
Protocol #19-1394, No Longer Enrolling: 3/17/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03237780
Protocol #X19-9999, No Longer Enrolling: 6/2/2020
Locations: Department Specific Free Standing Clinic, Highlands Ranch Hospital, University of Colorado Hospital;
Protocol #19-0591, No Longer Enrolling: 7/28/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03776812
Protocol #19-0327, No Longer Enrolling: 9/26/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03778931
Protocol #18-0156, No Longer Enrolling: 11/28/2019
;
This study aims to describe protein adduct (an experimental biomarker of acetaminophen exposure) concentrations in patients taking therapeutic doses of acetaminophen who develop a liver injury from a cause other than acetaminophen. To describe serum acetaminophen-cysteine adduct (an experimental biomarker of acetaminophen exposure) concentrations following hepatic embolization in patients taking therapeutic doses of acetaminophen three days before the procedure
Protocol #16-0031, No Longer Enrolling: 9/3/2021
Locations: CTRC Inpatient, Denver Health and Hospital Authority, Outpatient CTRC, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02911961
Protocol #19-0905, No Longer Enrolling: 2/23/2022
Locations: Lone Tree Medical Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03138512
Protocol #18-2404, No Longer Enrolling: 3/27/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03515551
Protocol #19-0457, No Longer Enrolling: 9/2/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02627443
Protocol #19-2018, No Longer Enrolling: 2/22/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03880019
Protocol #19-1146, No Longer Enrolling: 4/2/2021
Locations: Memorial Hospital Central, Memorial Hospital North, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03737994
The participant will be treated with microneedle arrays containing doxorubicin (D-MNA) or microneedle arrays containing placebo. The D-MNA or MNA-placebo is applied to the BCC lesion and secured to the skin with a self-adhesive bandage. The D-MNA is removed from the skin after 30 minutes. Each participant will receive three (3) weekly applications of the D-MNA unless a dose limiting toxicity (DLT) requires skipping or postponement of an application. The investigational product is chemotherapeutic agent doxorubicin (25 ug, 50 ug, 100 ug, or 200 ug) delivered to specific skin strata by a novel delivery system, MNA or placebo delivered to specific skin strata by MNA.
Protocol #19-0035, No Longer Enrolling: 12/18/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03646188
Protocol #19-0946, No Longer Enrolling: 3/21/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03964727
Protocol #19-0820, No Longer Enrolling: 1/6/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03383458
Protocol #19-1302, No Longer Enrolling: 7/1/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04060342
Protocol #15-6056, No Longer Enrolling: 12/25/2019
Locations: Memorial Hospital Central;
Protocol #19-2129, No Longer Enrolling: 1/29/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03896503
Protocol #19-6076, No Longer Enrolling: 11/17/2021
Locations: Greeley Campus, Harmony Campus, Medical Center of the Rockies, Poudre Valley Hospital;
More information available at ClinicalTrials.gov: NCT03975647
Protocol #19-6509, No Longer Enrolling: 12/6/2021
Locations: Memorial Hospital Central, Memorial Hospital North, Pikes Peak Regional Hospital;
More information available at ClinicalTrials.gov: NCT03975647
Protocol #19-0562, No Longer Enrolling: 1/22/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03755518
Protocol #18-0818, No Longer Enrolling: 3/21/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03502668
Protocol #19-0323, No Longer Enrolling: 10/13/2020
Locations: Anschutz Health and Wellness, UCD Anschutz Health & Wellness Center;
More information available at ClinicalTrials.gov: NCT03976193
Protocol #19-1147, No Longer Enrolling: 8/26/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03852511
Protocol #19-0821, No Longer Enrolling: 3/13/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03816358
Protocol #19-1913, No Longer Enrolling: 3/10/2021
Locations: Greeley Campus, Harmony Campus, Highlands Ranch Hospital, Lone Tree Medical Center, Medical Center of the Rockies, Memorial Hospital Central, Memorial Hospital North, Poudre Valley Hospital, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03793166
Protocol #19-1503, No Longer Enrolling: 3/23/2022
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04003636
Protocol #19-0549, No Longer Enrolling: 5/25/2021
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT03792256
Protocol #19-1346, No Longer Enrolling: 12/21/2019
Locations: University of Colorado Hospital;
Protocol #19-0536, No Longer Enrolling: 9/30/2020
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT03565900
Protocol #19-0642, No Longer Enrolling: 3/18/2022
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03897881
Protocol #19-6513, No Longer Enrolling: 11/2/2021
Locations: Memorial Hospital Central, Memorial Hospital North, Pikes Peak Regional Hospital;
More information available at ClinicalTrials.gov: NCT04456699
Protocol #19-6066, No Longer Enrolling: 7/25/2020
Locations: Memorial Hospital Central, Memorial Hospital North, Pikes Peak Regional Hospital;
More information available at ClinicalTrials.gov: NCT03840902
Protocol #19-6060, No Longer Enrolling: 11/20/2021
Locations: Greeley Campus, Harmony Campus, Medical Center of the Rockies, Poudre Valley Hospital;
More information available at ClinicalTrials.gov: NCT03646123
Protocol #19-2828, No Longer Enrolling: 4/8/2020
Locations: Greeley Campus, Harmony Campus, Medical Center of the Rockies, Memorial Hospital Central, Memorial Hospital North, Poudre Valley Hospital;
More information available at ClinicalTrials.gov: NCT03914612
Protocol #18-1349, No Longer Enrolling: 4/20/2022
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT03057054
Protocol #18-2000, No Longer Enrolling: 12/2/2020
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT01503086
Protocol #18-0198, No Longer Enrolling: 12/22/2020
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02900976
Protocol #19-1145, No Longer Enrolling: 8/24/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03809624
Protocol #19-2255, No Longer Enrolling: 4/10/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03691207
Protocol #19-1633, No Longer Enrolling: 11/27/2021
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT03581292
Protocol #19-1297, No Longer Enrolling: 11/14/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03132675
Protocol #19-1431, No Longer Enrolling: 8/20/2020
Locations: Lone Tree Medical Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03770000
Protocol #18-0554, No Longer Enrolling: 11/19/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03095612
Protocol #19-1074, No Longer Enrolling: 9/9/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03684785
Protocol #19-2445, No Longer Enrolling: 1/21/2022
Locations: Highlands Ranch Hospital, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04195750
Protocol #19-2163, No Longer Enrolling: 5/19/2021
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT03813147
Protocol #19-2560, No Longer Enrolling: 9/4/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04262336
Protocol #20-0365, No Longer Enrolling: 1/8/2021
Locations: Greeley Campus, Harmony Campus, Medical Center of the Rockies, Memorial Hospital Central, Memorial Hospital North, Poudre Valley Hospital, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04068103
Protocol #19-2724, No Longer Enrolling: 3/24/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03907488
Protocol #19-6517, No Longer Enrolling: 10/16/2021
Locations: Memorial Hospital Central, Memorial Hospital North, Pikes Peak Regional Hospital;
More information available at ClinicalTrials.gov: NCT04083235
Protocol #19-1069, No Longer Enrolling: 4/19/2022
Locations: Outpatient CTRC, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03986606
Protocol #19-6065, No Longer Enrolling: 4/2/2022
Locations: Greeley Campus, Harmony Campus, Medical Center of the Rockies, Poudre Valley Hospital;
More information available at ClinicalTrials.gov: NCT03840902
Protocol #19-2311, No Longer Enrolling: 11/16/2021
Locations: Outpatient CTRC, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03973333
Protocol #20-0360, No Longer Enrolling: 5/10/2022
Locations: Greeley Campus, Harmony Campus, Medical Center of the Rockies, Poudre Valley Hospital, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03997370
Protocol #19-1337, No Longer Enrolling: 4/12/2022
Locations: Lone Tree Medical Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03961698
Protocol #20-0580, No Longer Enrolling: 4/27/2022
Locations: Highlands Ranch Hospital, Lone Tree Medical Center, Memorial Hospital Central, Memorial Hospital North, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04094688
Protocol #19-2326, No Longer Enrolling: 12/4/2020
Locations: Greeley Campus, Harmony Campus, Medical Center of the Rockies, Memorial Hospital Central, Memorial Hospital North, Poudre Valley Hospital, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03952585
Protocol #19-2564, No Longer Enrolling: 4/7/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04204941
Protocol #19-3023, No Longer Enrolling: 1/7/2021
Locations: Childrens Hospital Colorado, University of Colorado Hospital;
Protocol #19-2707, No Longer Enrolling: 12/22/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04164901
Protocol #19-1977, No Longer Enrolling: 12/10/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03975647
Protocol #17-1756, No Longer Enrolling: 2/12/2021
Locations: Highlands Ranch Hospital, Lone Tree Medical Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03765918
Protocol #20-0563, No Longer Enrolling: 5/5/2021
Locations: Greeley Campus, Harmony Campus, Highlands Ranch Hospital, Lone Tree Medical Center, Medical Center of the Rockies, Memorial Hospital Central, Memorial Hospital North, Poudre Valley Hospital, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04268550
Protocol #16-2158, No Longer Enrolling: 4/12/2022
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02657005
To determine the efficacy of MMB versus DAN assessed by improvement in Myelofibrosis Symptom Assessment Form subjects with Primary Myelofibrosis, post-Polycythemia Vera myelofibrosis , or Post Essential Thrombocythemia Myelofibrosis who were previously treated with approved JAK inhibitor therapy.
Protocol #19-2520, No Longer Enrolling: 5/19/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04173494
Protocol #19-1342, No Longer Enrolling: 4/9/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03778957
Protocol #20-0564, No Longer Enrolling: 11/21/2020
Locations: Greeley Campus, Harmony Campus, Highlands Ranch Hospital, Lone Tree Medical Center, Medical Center of the Rockies, Memorial Hospital Central, Memorial Hospital North, Poudre Valley Hospital, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04173507
Protocol #20-0357, No Longer Enrolling: 10/21/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04169711
Protocol #20-0246, No Longer Enrolling: 11/17/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04520867
Protocol #19-1588, No Longer Enrolling: 4/7/2021
Locations: Rocky Mountain Regional VA Medical Center;
More information available at ClinicalTrials.gov: NCT03768414
Protocol #19-1711, No Longer Enrolling: 1/20/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03897036
Protocol #19-2242, No Longer Enrolling: 3/30/2022
Locations: Outpatient CTRC, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04088318
This is a 12-week combined aerobic and resistance exercise intervention in breast cancer survivors. Before and after the intervention, women will undergo measures of appetite, energy intake, body composition, and resting metabolic rate.
Protocol #19-3032, No Longer Enrolling: 1/8/2022
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04576247
Protocol #19-2999, No Longer Enrolling: 7/8/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04191096
Protocol #20-0262, No Longer Enrolling: 7/21/2021
Locations: Lone Tree Medical Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04329949
Protocol #20-0138, No Longer Enrolling: 4/26/2022
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04541407
Protocol #19-2862, No Longer Enrolling: 2/5/2022
Locations: City of Hope Cancer Center, Mayo Clinic, Rochester, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04634110
Protocol #20-1106, No Longer Enrolling: 4/12/2022
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT04158739
Protocol #18-1990, No Longer Enrolling: 10/3/2020
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT03497273
Protocol #20-1346, No Longer Enrolling: 10/23/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03777657
Protocol #19-1581, No Longer Enrolling: 8/24/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04099251
Protocol #20-0727, No Longer Enrolling: 12/3/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03348514
Protocol #20-0881, No Longer Enrolling: 12/1/2021
Locations: Highlands Ranch Hospital, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04338269
Protocol #20-1267, No Longer Enrolling: 12/17/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04479436
Protocol #18-2128, No Longer Enrolling: 2/9/2022
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04508647
Protocol #20-0605, No Longer Enrolling: 3/2/2022
Locations: Highlands Ranch Hospital, Lone Tree Medical Center, Outpatient CTRC, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04452214
Protocol #19-0987, No Longer Enrolling: 4/13/2021
Locations: Department Specific Free Standing Clinic, University of Colorado Hospital;
Protocol #20-0746, No Longer Enrolling: 4/13/2022
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03504397
Protocol #20-0036, No Longer Enrolling: 8/10/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04132817
Protocol #20-0261, No Longer Enrolling: 5/18/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04607200
Protocol #19-1195, No Longer Enrolling: 1/30/2021
Locations: Lone Tree Medical Center, University of Colorado Hospital, University of Michigan;
More information available at ClinicalTrials.gov: NCT04535102
Protocol #20-1830, No Longer Enrolling: 5/11/2022
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04395508
A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast Conserving Therapy
Protocol #20-1420, No Longer Enrolling: 6/30/2021
Locations: Memorial Hospital Central, Memorial Hospital North;
More information available at ClinicalTrials.gov: NCT03448926
Protocol #20-0003, No Longer Enrolling: 6/4/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04149574
Protocol #20-1306, No Longer Enrolling: 3/29/2022
Locations: Highlands Ranch Hospital, Lone Tree Medical Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04461600
Protocol #19-1687, No Longer Enrolling: 5/4/2022
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT00000000
Protocol #20-0233, No Longer Enrolling: 4/16/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04305041
Protocol #20-1210, No Longer Enrolling: 4/6/2022
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT04154189
Protocol #17-1337, No Longer Enrolling: 4/30/2021
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02926612
Protocol #20-2733, No Longer Enrolling: 10/13/2021
Locations: Outpatient CTRC, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03928314
Protocol #20-2167, No Longer Enrolling: 3/30/2022
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04494425
Protocol #20-0281, No Longer Enrolling: 3/16/2022
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03577028
Protocol #20-1441, No Longer Enrolling: 9/29/2021
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT04225676
Protocol #19-3018, No Longer Enrolling: 3/3/2022
Locations: Rocky Mountain Regional VA Medical Center;
More information available at ClinicalTrials.gov: NCT03447769
Protocol #20-1837, No Longer Enrolling: 3/25/2022
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04410445
Protocol #UCH13-1230, No Longer Enrolling: 1/19/2022
Locations: Memorial Hospital Central, Memorial Hospital North, Pikes Peak Regional Hospital;
More information available at ClinicalTrials.gov: NCT01901094
Protocol #20-1970, No Longer Enrolling: 8/19/2021
Locations: Outpatient CTRC, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04161885
Protocol #21-3259, No Longer Enrolling: 11/19/2021
Locations: Lone Tree Medical Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04602117
Protocol #20-2060, No Longer Enrolling: 11/17/2021
Locations: Greeley Campus, Harmony Campus, Highlands Ranch Hospital, Lone Tree Medical Center, Medical Center of the Rockies, Memorial Hospital Central, Memorial Hospital North, Poudre Valley Hospital, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04478266
Protocol #21-2686, No Longer Enrolling: 3/26/2022
Locations: Outpatient CTRC, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04644237
Protocol #20-2675, No Longer Enrolling: 5/4/2022
Locations: Lone Tree Medical Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03250676
Protocol #20-3007, No Longer Enrolling: 3/3/2022
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04340843
Protocol #21-4045, No Longer Enrolling: 3/4/2022
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04939701
To estimate the objective response rate (ORR) with valemetostat tosylate monotherapy treatment in relapsed/refractory peripheral T-cell lymphoma (R/R PTCL, including R/R adult T-cell leukemia/lymphoma (ATL). Subjects with R/R ATL are to be enrolled in a separate cohort and will be analyzed independently.
Protocol #21-3415, No Longer Enrolling: 5/11/2022
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04703192
The primary objective of this study is to provide extended access to momelotinib (MMB) and assess long-term safety in 4 cohorts of subjects who are currently receiving treatment with MMB and have not experienced progression of disease: Cohort 1: Study GS-US-352-0101, subjects with primary myelofibrosis (PMF) or post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF) Cohort 2: Study GS-US-352-1214, subjects with PMF or post-PV/ET MF Cohort 3: Study GS-US-352-1154, subjects with PMF or post-PV/ET MF Cohort 4: Study SRA-MMB-301, subjects with PMF or post-PV/ET MF
Protocol #21-4793, No Longer Enrolling: 4/15/2022
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03441113
Protocol #17-2168C, No Longer Enrolling: 3/5/2022
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT03213665
Protocol #13-0131, No Longer Enrolling: 6/10/2021
Locations: CTRC-adult, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT01794143
To assess whether, in participants with pre-diabetes, oral daily vitamin D3 (cholecalciferol) supplementation reduces the rate of progression from prediabetes to diabetes.
Protocol #14-2402, No Longer Enrolling: 11/14/2019
Locations: CTRC-adult, University of Colorado Hospital;
This study plans to learn more about the best eating patterns for weight loss. Specifically, this study is being done to try to determine if intermittent fasting is as effective for weight loss as daily calorie restriction. In this study, we will be evaluating how your body weight, body composition, laboratory values, energy expenditure, and eating and exercise behaviors change during a 12-month weight loss program. We will also evaluate how your biology, life experiences, thought processes, behaviors, and environment predict how much weight you lose and how well you follow the diet and exercise recommendations in the study.
Protocol #17-0369, No Longer Enrolling: 6/15/2021
Locations: Anschutz Health and Wellness, UCD Anschutz Health & Wellness Center, University of Colorado Hospital;
This study is a clinical research study consisting of 2 different periods (in the Core phase) with a total expected duration of 48 weeks and the first 12 weeks being a double-blind placebo controlled portion and then 36 weeks of study drug treament, followed by an optional extension phase for an additional 52 weeks (in which case the total duration of study participation will be up to 100 weeks). It is sponsored by the pharmaceutical company named Novartis (the ?Sponsor?). Around 69 patients will join this study in approximately 35 centers located in different countries (around 12) across the world. The purpose of this study is to confirm the effectiveness and safety of osilodrostat in treating patients with Cushing's Disease.
Protocol #17-0483, No Longer Enrolling: 3/10/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02697734
Protocol #17-0399, No Longer Enrolling: 2/10/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03252353
Protocol #17-0366, No Longer Enrolling: 7/22/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03373435
Protocol #17-2118, No Longer Enrolling: 1/6/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03452228
Protocol #18-0756, No Longer Enrolling: 2/10/2021
Locations: University of Colorado Hospital;
Protocol #18-0369, No Longer Enrolling: 5/13/2021
Locations: University of Colorado Hospital;
Protocol #18-2230, No Longer Enrolling: 10/26/2020
Locations: Childrens Hospital Colorado;
Protocol #18-1934, No Longer Enrolling: 10/8/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03770637
Protocol #18-2435, No Longer Enrolling: 10/6/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03285308
Protocol #19-0120, No Longer Enrolling: 5/13/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03596450
Protocol #17-1543, No Longer Enrolling: 8/29/2020
Locations: Childrens Hospital Colorado;
Protocol #18-2130, No Longer Enrolling: 12/21/2020
Locations: Childrens Hospital Colorado;
Protocol #17-1317, No Longer Enrolling: 8/20/2021
Locations: Childrens Hospital Colorado, Department Specific Free Standing Clinic;
Protocol #17-1809, No Longer Enrolling: 5/12/2021
Locations: Childrens Hospital Colorado;
Protocol #18-1716, No Longer Enrolling: 12/7/2020
Locations: Childrens Hospital Colorado;
Protocol #19-1230, No Longer Enrolling: 2/17/2022
Locations: Childrens Hospital Colorado;
Participation will include: Blood draws and questionnaires; Assessments of body composition, energy metabolism, and glucose control; Membership to the Anschutz Health and Wellness Center; Monetary compensation
Protocol #21-3690, No Longer Enrolling: 10/23/2021
Locations: Outpatient CTRC, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT05031221
This study uses colonic biopsies to compare immune cell function and gut microbiome between those with IBD, AS, AS/IBD overlap, and healthy controls. To evaluate the relationship between the colonic microbiome and the immune system in AS, IBD, AS+IBD, and healthy controls.
Protocol #14-1507, No Longer Enrolling: 7/6/2021
Locations: Colorado Research Center, Denver Health and Hospital Authority, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02389075
DUR-928 (investigational drug)
Protocol #18-0123, No Longer Enrolling: 1/6/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03394781
The safety of medications to treat UC and CD during pregnancy and lactation is of significant interest of childbearing potential, as these medications may be transferred in utero or though breast milk form nursing mothers to their newborns. It is unknown whether vedolizumab is present in human breast milk.
Protocol #16-0066, No Longer Enrolling: 6/9/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02559713
The purpose of this study is to determine if a newer type of metal stent with a plastic covering, called the AXIOSTM stent, is safe and effective in draining your WON.
Protocol #18-0442, No Longer Enrolling: 12/3/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03525808
Protocol #18-1144, No Longer Enrolling: 1/6/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03554759
This is a double-blind, placebo-controlled, parallel-arm, multicenter study comparing the safety, tolerability, and efficacy of CP101 treatment relative to placebo in adults with previously treated recurrent CDI. Subjects who are experiencing recurrent CDI will undergo screening procedures. Subjects who meet eligibility criteria will be randomized to study drug. Approximately 200 subjects (100 subjects per treatment group) will be randomized in a 1:1 ratio to receive CP101 (6 1011 bacteria) or placebo. The treatment duration will be 1 day, including active drug (CP101) and placebo. Subjects will be monitored for recurrence of CDI, safety, and tolerability for 24 weeks following Randomization. The primary efficacy and safety endpoints will be evaluated at 8 weeks post-treatment, and all subjects will continue to be followed for an additional 16 weeks for safety and recurrence of CDI. To qualify for the study, subjects must be experiencing recurrent CDI defined as: a) 3 episodes of CDI, with 2 episodes occurring within the previous 12 months (inclusive of the current episode); OR b) 2 episodes of CDI occurring within the previous 6 months (inclusive of the current episode) AND 65 years of age or older. Additionally, to qualify, recurrent CDI subjects must have received standard-of-care CDI antibiotics for the most recent CDI episode (for 10-21 days, with exact duration, antibiotic type, and dose at the discretion of the Investigator) and have an adequate clinical response, defined as 3 unformed stools in 24 hours for 2 or more consecutive days immediately prior to Randomization.
Protocol #18-1166, No Longer Enrolling: 9/28/2021
Locations: Outpatient CTRC, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03497806
The Treatment Period begins with treatment assignment and lasts for 8 weeks. Patients will be stratified by whether they have, or do not have, erosive esophagitis on the screening EGD, and by their baseline heartburn severity level (average heartburn severity score over the last 7 days prior to randomization of <3 vs. ≥3; see Criteria for Evaluation, below) and randomly assigned within each stratum to placebo or 1500 mg IW-3718 BID (1:1). The treatment randomization schedule will be managed by a central vendor. Enrollment will be monitored to ensure that no single center contributes > 10% of the targeted study enrollment, unless otherwise approved by the Medical Monitor. Study drug will be taken immediately after the morning and evening meals. Patients will continue to take their PPI approximately 30-60 minutes before breakfast each day and to use the eDiary to provide their daily assessments (GERD symptoms and assessment of sleep), weekly assessments (degree of relief of GERD symptoms, symptom bothersomeness, and treatment satisfaction questions). At the end of the treatment period study medication will be discontinued and patients will return for an End-of-Treatment (EOT) Visit. All patients who have erosive esophagitis (LA classification A-D) on EGD at Screening and completed ≥4 weeks of treatment will have a repeat EGD at their EOT Visit. Patients will also complete all End-of-Treatment assessments
Protocol #18-2021, No Longer Enrolling: 6/10/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03327727
Protocol #20-0584, No Longer Enrolling: 4/2/2021
Locations: Greeley Campus, Harmony Campus, Medical Center of the Rockies, Memorial Hospital Central, Memorial Hospital North, Poudre Valley Hospital;
More information available at ClinicalTrials.gov: NCT04175912
Volixibat is an experimental treatment, meaning that it has not yet been approved by the US Food and Drug Administration or any worldwide regulatory body. Volixibat is a medicine that lowers circulating bile acid levels that are believed to lead to the itching in patients with PSC. There are no other medicines approved to treat itching in patients with PSC. This is the first time volixibat will be used in patients with PSC. In the first part of this study, called the “Core Study,” the study medicine will be compared with a placebo for a period of 28 weeks. A placebo is a capsule that looks exactly like the study medicine but does not contain any active ingredient. At any time during this part of study, you may be given volixibat or placebo. Whether you receive volixibat or placebo will be decided randomly (by chance, like flipping a coin/rolling a die). In the Core Study, between 50% and 67% of participants will receive volixibat. To make this study fair, for part of the study, you and the study doctor will not be told which medicine or placebo you will receive. This is called “blinding.” In case of an emergency, the study doctor will be able to look up the medicine or placebo you are taking/receiving at any time. In the next part of this study, called the “Open-Label Extension,” all eligible participants who choose to continue will receive volixibat for up to 2 years. The primary and secondary objectives and endpoints will be evaluated in participants with PSC who have a baseline score of ≥4 on the Adult Itch-Reported Outcome (ItchRO), as assessed during the single-blind, placebo run-in period during the core study.
Protocol #20-2820, No Longer Enrolling: 11/1/2021
Locations: Outpatient CTRC, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04663308
This study plans to learn more about muscle wasting in children with chronic liver disease. We know that older people with chronic liver disease can have severe loss of muscle and that this increases their risk of poor outcomes associated with their liver disease. We hope to find out more information about if muscle wasting is happening in children with liver disease and what may be driving the loss of muscle mass.
Protocol #21-3275, No Longer Enrolling: 3/2/2022
Locations: Childrens Hospital Colorado;
We hope to figure out the following aims: Aim 1: Describe the timing and duration of fibrinolysis resistance in pediatric liver transplant recipients pre-operatively through post-operative day 5 with tEG and t-PA TEG, and contrast coagulation profiles to adult liver transplant recipients during a similar time course. Aim 2: Determine if fibrinolysis shutdown on post-operative day 1 is associated with hepatic artery thrombosis. Aim 3: Characterize a targeted coagulation proteome of pediatric liver transplant recipients that remain in fibrinolysis shutdown on post-operative day 1 versus liver recipients that recover to normal fibrinolysis function.
Protocol #18-1295, No Longer Enrolling: 3/2/2022
Locations: Childrens Hospital Colorado;
Specific Aim 1- Determine the correlation of EoE, EG, EGE and EC clinical outcome measures (COMs) with mucosal eosinophilia. Primary Objective-To perform a prospective, multicenter, pediatric and adult longitudinal study to determine the correlation of COMs (PROs, QoL and endoscopy) with the established biomarker of peak mucosal eosinophil count (Phase 1). Specific Aim 2- Determine the correlation of the molecular profile for EoE, EG, EGE and EC with clinical outcome measures (COMs) and mucosal eosinophilia. Primary Objective-To perform a prospective, multicenter, pediatric and adult exploratory study to compare the transcriptomes (EoE transcriptome, EG-transcriptome , EGE-transcriptome and EC transcriptome) with their respective peak mucosal eosinophil counts and respective COMs generated in Aim 1. Specific Aim 1 Secondary Objective-To determine how the EoE, EG, EGE and EC COMs and tissue histology change over time in order to determine a better understanding of the natural history of the disease and response to therapy. (Phase 2) Specific Aim 2 Secondary Objective- To perform an exploratory study to compare the four transcriptomes to each other in order to identify patterns of similarity and differences in order to understand the etiological relationship of these diseases and potential therapeutic strategies moving forward.
Protocol #15-1913, No Longer Enrolling: 3/2/2022
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02523118
Protocol #19-2668, No Longer Enrolling: 3/2/2022
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT04004611
Participants will come into the clinic for 5 visits which will last 1.5-3.5 hours long. Each visit has an Audiologist and an Otologist component in it. Each participant will need to complete daily diary entries by calling into phone number and answering some questions.
Protocol #18-1269, No Longer Enrolling: 3/2/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03664674
Protocol #18-1057, No Longer Enrolling: 12/3/2019
Locations: University of Colorado Hospital;
OptiNose intends to study the efficacy and safety of OPN-375 in subjects with chronic sinusitis.
Protocol #18-2823, No Longer Enrolling: 9/17/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03781804
Protocol #19-2598, No Longer Enrolling: 7/23/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04237207
A new study is looking at a device that would strengthen the muscles of the mouth to make eating and drinking easier for those who have trouble swallowing. Participants will be randomized to either the group using the investigational device for tongue exercise or the group using standard of care tongue depressors. All participants will receive compensation for participating. To develop a low-cost device that improves patient outcomes by eliciting the same methods of action of existing higher cost devices. To assess if exercising the tongue with this novel device can achieve increased tongue strength among individuals with Parkinson's disease.
Protocol #19-1850, No Longer Enrolling: 11/18/2020
Locations: University of Colorado Hospital;
Protocol #19-2940, No Longer Enrolling: 4/28/2021
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT00000000
If you are to take part in this study, you would be able to come to the clinic for 6 visits which lasts about 110 days. Visit 1 (Screening) and 2 (Baseline) will have about the same procedures done: 1. We will ask about your demographics, medical history, and current medications and check you vital signs 2. We will ask you some questionnaires 3. We will do a blood draw and take your urine for lab tests to check the safety of the medication 4. The Provider will examine your ears and an Audiologist will check your hearing 5. You will receive an electronic Daily Diary which you will need to complete every night of the trial 6. During Visit 2, if you qualify, you will be randomized in to the placebo or the investigational product group. This is a completely blind trial. The Providers, Audiologists, Clinical Research Staff and yourself won't know which group you are in. You will receive the injection. For Visits 3 – 5: 1. We will ask you about your current medications, changes to your health, and take your vital signs 2. We will ask you some questionnaires 3. The Provider will examine your ears and an Audiologist will check your hearing For Visit 6: 1. We will ask you about your current medications, changes to your health, and take your vital signs 2. We will ask you some questionnaires 3. We will do a blood draw and take your urine for lab tests to check the safety of the medication 4. The Provider will examine your ears and an Audiologist will check your hearing
Protocol #21-3418, No Longer Enrolling: 2/4/2022
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04829214
Protocol #16-0145, No Longer Enrolling: 2/10/2021
Locations: Childrens Hospital Colorado;
Protocol #19-0396, No Longer Enrolling: 2/10/2022
Locations: Childrens Hospital Colorado;
Protocol #19-2807, No Longer Enrolling: 6/6/2020
Locations: Lone Tree Medical Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04240808
Protocol #16-0614, No Longer Enrolling: 8/18/2021
Locations: Comprehensive Women's Health Center, Comprehensive Womens Health Center;
Protocol #15-1052, No Longer Enrolling: 2/4/2022
Locations: CTRC Inpatient, Outpatient CTRC, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02653092
This study plans to learn more about the relationship between fertility and obesity.
Protocol #15-0474, No Longer Enrolling: 3/2/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02478775
The goal of this study is to vary the amount of F-TAF dosing and see if the drug levels in dried blood spots (DBS) change in a predictable way.
Protocol #16-0972, No Longer Enrolling: 10/16/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02962739
If you join the study, you will complete the following research procedures over the course of 2 study visits: Informed consent, physical exam and medical history, body composition test, blood draw and fat biopsy. This research study plans to learn more about where the fat cells in your body come from. Understanding the origin of fat cells is important because it may help to determine the health of fat cells and why fat that is stored in some places of your body is more "unhealthy" than other fat.
Protocol #15-1779, No Longer Enrolling: 6/16/2021
Locations: Outpatient CTRC, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02654925
Participants needed for a research study that plans to examine the effects of age and body weight on food intake, appetite regulation, and brain responses to food.
Protocol #15-1511, No Longer Enrolling: 1/26/2022
Locations: Outpatient CTRC, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02721303
Protocol #16-2739, No Longer Enrolling: 4/30/2021
Locations: University of Colorado Hospital;
Protocol #17-0092, No Longer Enrolling: 6/17/2021
Locations: University of Colorado Hospital;
Over the past 25 years, RALS has been increasingly, and often incorrectly, diagnosed and has emerged as a point of controversy and confusion. Despite the limitations of current diagnostic tests and therapeutic strategies, recent advances in gastoresophageal reflux disease offer tremendous potential for RALS diagnosis and treatment. Newer diagnostic tools are able to assess physiologic properties of RALS. Thus, this study will address three crucial gaps impacting the clinical approach to RALS: 1) Paucity of diagnostic tests that predict clinically relevant outcomes, 2) undefined clinical role of UES augmentation, and 3) deficiency or cost-effective and personalized approaches.
Protocol #18-0205, No Longer Enrolling: 5/3/2022
Locations: University of Colorado Hospital;
We are looking for healthy men to participate in a research study on the effects of sleep restriction on bone. The purpose of this research is to understand how shortened sleep affects bone metabolism. The study includes an intervention phase consisting of a 1-week outpatient and 8-night inpatient stay. Participants will be observed after discharge from the intervention phase for 3 weeks. Principal Investigator, Christine Swanson, MD, MCR (COMIRB #18-0015)
Protocol #18-0015, No Longer Enrolling: 10/8/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03733483
Protocol #19-0802, No Longer Enrolling: 2/21/2020
Locations: Barbara Davis Center, UCD Barbara Davis Center;
What you receive for participating: -Personalized information about your energy expenditure ("metabolism") -Five total days of food -Monetary compensation Test whether accelerometer-based measures of physical activity from Actigraph and ActivPAL accelerometers can be used to improve the calculation of TEF in whole room calorimeter studies.
Protocol #20-0191, No Longer Enrolling: 9/3/2021
Locations: University of Colorado Hospital;
Protocol #19-3006, No Longer Enrolling: 2/4/2021
Locations: CHOC ? Children?s Hospital of Orange County, UCLA - University of California, UCLA, Jonsson Cancer Center, University of Colorado Hospital;
Protocol #21-2886, No Longer Enrolling: 4/20/2022
Locations: Brain Imaging Center (BIC), Outpatient CTRC, University of Colorado Hospital;
The purpose of this study is to learn more about where the fat tissue in your body originates. For many years it has been thought that all fat cells come from cells that are from the fat tissue itself, but now we know it is possible that some fat cells may originally come from the bone marrow. Understanding the origin of fat cells is important because it may help to determine the health of fat cells. You are being asked to be in this research study because you are a person over the age of 18 who has had a hematopoietic stem cell transplant or has chronic phase chronic myeloid leukemia (CML). To understand if some fat cells (adipocytes) may originally come from cells in the bone marrow. Understanding the origin of fat cells is important because it may help to determine the health of fat cells and why fat that is stored in some places of your body is more unhealthy than other fat.
Protocol #13-0026, No Longer Enrolling: 8/19/2021
Locations: University of Colorado Hospital;
Protocol #17-0423, No Longer Enrolling: 1/6/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03035474
Assess your medical care Help researchers better understand your medical treatment and health outcomes Provide an understanding on how diseases impact your daily life Provide you with more information about heart disease
Protocol #17-6148, No Longer Enrolling: 6/27/2020
Locations: Memorial Hospital Central;
Protocol #17-1042, No Longer Enrolling: 7/6/2021
Locations: CTRC Inpatient, University of Colorado Hospital;
Protocol #17-1249, No Longer Enrolling: 5/20/2022
Locations: Harmony Campus, Medical Center of the Rockies, Memorial Hospital Central, Memorial Hospital North, Poudre Valley Hospital, University of Colorado Hospital;
Protocol #17-1343, No Longer Enrolling: 1/15/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02929329
Protocol #17-1506, No Longer Enrolling: 11/14/2019
Locations: University of Colorado Hospital;
The objective of this study is to understand real-world treatment patterns, as well as the reasons and barriers for treatment changes in heart failure patients with reduced ejection fraction.
Protocol #16-6062, No Longer Enrolling: 5/20/2020
Locations: Memorial Hospital Central;
The purpose of this trial is to establish the safety and efficacy of the Edwards SAPIEN 3 THV device in patients with severe, calcific, aortic stenosis who are at low operative risk for SAVR.
Protocol #16-6069, No Longer Enrolling: 10/1/2019
Locations: Harmony Campus, Medical Center of the Rockies;
More information available at ClinicalTrials.gov: NCT02675114
Protocol #16-2506, No Longer Enrolling: 10/9/2021
Locations: University of Colorado Hospital;
Protocol #17-6134, No Longer Enrolling: 1/22/2022
Locations: Greeley Campus, Harmony Campus, Long's Peak Hospital, Longs Peak Hospital, Medical Center of the Rockies, Yampa Valley Medical Center;
More information available at ClinicalTrials.gov: NCT03042104
WATCH-TAVR is a prospective, multicenter, randomized event-driven controlled trial.
Protocol #18-6002, No Longer Enrolling: 11/7/2020
Locations: Harmony Campus, Medical Center of the Rockies;
More information available at ClinicalTrials.gov: NCT03173534
The MANAGE-HF study is a multi-center, global, prospective, open label, multi-phase trial. Phase I will be non-randomized. Phase II will be randomized. 1) To evaluate and optimize HeartLogic? Heart Failure Diagnostics (called HeartLogic from here on) clinical integration and the alert management process (Phase I) 2. To evaluate HeartLogic in regards to patient outcomes of death and heart failure hospitalizations (Phase II)
Protocol #18-6028, No Longer Enrolling: 5/20/2020
Locations: Memorial Hospital Central, Memorial Hospital North;
More information available at ClinicalTrials.gov: NCT03237858
This study is a prospective, randomized, multi-center, global investigation to determine the safety and effectiveness of the WATCHMAN Device for subjects with non-valvular atrial fibrillation who are deemed not suitable for anticoagulation therapy to reduce the risk of stroke.
Protocol #18-6501, No Longer Enrolling: 1/21/2020
Locations: Memorial Hospital Central;
More information available at ClinicalTrials.gov: NCT02928497
The purpose of this study is to test the safety and effectiveness of the study drug, avatrombopag, in subjects with thrombocytopenia undergoing an operation. Patients will receive either 60mg or 80mg of avatrombopag once daily by mouth for 5 days prior to surgery
Protocol #18-0546, No Longer Enrolling: 9/15/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03326843
Protocol #18-6020, No Longer Enrolling: 1/22/2022
Locations: Medical Center of the Rockies;
Once the subject meets entry criteria, the study will enroll into a 25 week study. The subject will have subcutaneous injections once weekly and be expected to return to clinic every 6 weeks. The other weekly visits can be done in the subject's location of choice (i.e. home/work). There are multiple blood draws required for this study at certain time points. Other procedures that the subject will complete during the study are: a complete physical exam, EKGs, laboratory assessments, 6 minute walks, 2 right heart caths - one at the beginning and one at the end of the study and daily blood pressures. The subject will be given a home B/P monitor to use. During this study, the subject has a 66% chance of getting active study drug and a 33% change of getting a placebo. Once the subject completes the study, the subject will have the option to enroll into the open label study during which he/she will be given the active study drug.
Protocol #18-0915, No Longer Enrolling: 10/1/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03556020
If you agree to join the study, screening tests will be performed while you are in the hospital to assess your eligibility for the study. If you are eligible to take part in the study, you will be randomized to receive either the study drug or placebo. ?Randomized? means that you will be assigned by chance, like flipping a coin, to take the study drug (CSL112) or the placebo. You will have a 50/50 chance of receiving either CSL112 or placebo. Both the study drug and placebo will be given by intravenous (IV) infusion which means slowly pumping the drug into your body through a small tube that is inserted into a vein. The infusion will last approximately 2 hours. You will receive up to four (4) infusions of either the study drug or placebo weekly for 4 weeks; each infusion is to be given at least 5 days apart. All 4 infusions should be administered within 30 days of you receiving your first infusion. Additional study visits will occur throughout the next year to assess for any new health problems, side effects, or changes in your medical conditions. This is a double-blind study, which means you, your Study Doctor, and the study staff will not know which treatment you are getting, but your Study Doctor can find out if there is an emergency, if it is critical to know for your health, or after the study has ended and the results have been analyzed. Your participation in the study will be approximately 1 year (365 days). This includes the Screening Period (1 visit), an Active Treatment Period (which includes 4 weekly infusion visits and a follow-up visit for safety) and a Follow-Up Period (which includes 5 visits) to assess any new health problems or side effects you may have experienced since your last study visit and your overall well-being. This study will have 11 study visits, 2 of which may be conducted by telephone during the Follow-Up period.
Protocol #18-6051, No Longer Enrolling: 8/12/2020
Locations: Memorial Hospital Central;
More information available at ClinicalTrials.gov: NCT03473223
Subjects enrolled in this trial will be randomly assigned to receive either Empagliflozin 10 mg or placebo for 12 weeks.
Protocol #18-0925, No Longer Enrolling: 9/9/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03448406
Participants will be randomly assigned to empagliflozin or placebo. Participants will take the study medication (empagliflozin or placebo) for 12 weeks.
Protocol #18-0926, No Longer Enrolling: 9/9/2021
Locations: Outpatient CTRC, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03448419
The primary objective of this study is to evaluate the efficacy of CSL112 on reducing the risk of MACE (CV death, MI, or stroke) from the time of randomization through 90 days in subjects with ACS (diagnosed with STEMI or NSTEMI)
Protocol #18-6081, No Longer Enrolling: 4/13/2021
Locations: Harmony Campus, Medical Center of the Rockies;
More information available at ClinicalTrials.gov: NCT03473223
Umbilical cord blood is collected at birth and shipped to ReGen Theranostics, Inc for manufacturing. The umbilical cord blood mononuclear cells (MNC) are isolated from the cord blood and frozen. The cells are then transported to the study site when the patient undergoes the Glenn surgery. This study will evaluate the efficacy and safety of UCB-MNC intramyocardial injections performed during Stage II surgical palliation by focusing on short and long-term cardiac function leading up to the pre-op work-up for Stage III surgical palliation.
Protocol #18-2012, No Longer Enrolling: 3/2/2022
Locations: Childrens Hospital Colorado;
PASCAL System (vs. MitraClip) in treatment of symptomatic degenerative mitral regurgitation
Protocol #18-6126, No Longer Enrolling: 1/22/2022
Locations: Harmony Campus, Medical Center of the Rockies;
More information available at ClinicalTrials.gov: NCT03706833
This is a multicenter, randomized, blinded and placebo controlled study in subjects with WHO group 1 Pulmonary Arterial Hypertension who will recieve inhaled GB002 or matching placebo for 14 days. The subject will have to visit the clinic for screening and on days 1, 2, 8 and 14. The patient has the option of having a visiting nurse come to them on days 3 to 7 to verify that they are following instrctions for dosing of the study drug and completing their study diary correctly. There will also be a follow up telephone call on days 15 and 42 to assess the patient's physical status and record any additional medications being taken. On day 1 and day 14, the visit will last up to 6 hours and the patient will have 5 blood draws during that time to assess drug levels in the blood and on days 2 and 8, the visi will last up to 2 hours and the patient will have one blood level drawn on these days.
Protocol #18-2672, No Longer Enrolling: 6/16/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03926793
Patients diagnosed with an abdominal aortic or aortoiliac aneurysm who are considered candidates for endovascular repair and who meet the study eligibility criteria may be screened for enrollment in the study
Protocol #19-6501, No Longer Enrolling: 6/24/2020
Locations: Memorial Hospital Central;
More information available at ClinicalTrials.gov: NCT03298477
A Prospective, Multi-Center, Single Arm Study to obtain “Real World” Clinical Data and Characterize the Acute and Long-Term Performance of the Micrusframe and Galaxy Coils for the Endovascular Treatment of Intracranial Aneurysms
Protocol #19-6503, No Longer Enrolling: 4/4/2020
Locations: Memorial Hospital Central;
More information available at ClinicalTrials.gov: NCT03642639
The ACTIVE Trial is a prospective, randomized, multicenter trial. Patients with clinically significant functional mitral regurgitation will be randomized 2:1 to receive either transcatheter mitral valve repair with the Edwards Cardioband System plus guideline directed medical therapy (GDMT) or GDMT alone.
Protocol #17-2107, No Longer Enrolling: 11/14/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03016975
The Edwards PASCAL System is intended for the percutaneous reconstruction of an insufficient mitral valve in patients with clinically significant, symptomatic mitral regurgitation and: New York Heart Association (NYHA) Functional Class II, III and ambulatory IV heart failure The primary regurgitant jet is non-commissural. If a secondary jet exists, it must be considered clinically insignificant
Protocol #18-0876, No Longer Enrolling: 1/6/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03170349
This clinical study is a prospective, multicenter, single-arm clinical evaluation of the Multi-Electrode Radiofrequency (RF) Balloon catheter. The purpose of this study is to evaluate the overall safety and effectiveness of the Multi-Electrode RF Balloon catheter, in conjunction with the Multi-Electrode Circular Diagnostic catheter and Multi-Channel RF Generator, for the treatment of drug refractory Paroxysmal Atrial Fibrillation (PAF). Embedded within the Main Study will be a Neurological Assessment Evaluable (NAE) subset and a Cardiac Computed Tomography (CT) or Magnetic Resonance Angiogram (MRA) image (CT/MRA) subset with consecutive enrollment and a prospective design. The same subject can participate in both the NAE and cardiac CT/MRA subsets. The study will enroll subjects with drug refractory, symptomatic PAF who are candidates for catheter ablation. The first 1-3 subjects for each ablating physician will be considered roll-in subjects to verify consistent workflow for study device components and to minimize any learning curve effects. The roll-in subjects will not be included in the NAE subset, cardiac CT/MRA subset, or in the primary endpoint analyses. The roll-in phase will include a maximum of 240 subjects and the main study phase will include a maximum of 400 evaluable subjects. Subjects will be evaluated prior to the procedure, prior to discharge, and post procedure at 7 days (7-14 days), 1 month (23-37 days), 3 months (76- 104 days), 6 months (150-210 days), and 12 months (315-405 days) unless otherwise specified in the protocol.
Protocol #19-1679, No Longer Enrolling: 4/17/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03683030
This is a study for patients that have a heart condition in which the upper chambers of your heart beat irregularly. This condition, also known as atrial fibrillation, can cause blood clots to form in an area of your heart called the left atrial appendage (LAA). Everyone has a LAA, which is like a pouch on the top of your heart, and it developed along with the other parts of the heart before birth. If a clot forms here, it can increase your chances of having a stroke or other related problems. Because you have atrial fibrillation, it is believed that if the LAA is closed, then blood clots might not be able to form in that area. The current standard of care to prevent stroke in patients with atrial fibrillation is long-term oral anticoagulation (OAC) therapy (blood thinner medication) or, in appropriately selected patients, implant of the commercial WATCHMANTM device followed by short-term OAC therapy.
Protocol #19-6506, No Longer Enrolling: 9/10/2021
Locations: Memorial Hospital Central;
More information available at ClinicalTrials.gov: NCT03795298
This is a clinical study sponsored by Amgen Inc. It is a study being done for patients that are at high risk for experiencing a cardiovascular event (like a heart attack or stroke). Elevated cholesterol, in particular low-density lipoprotein cholesterol (LDL-C), can lead to obstructing fatty deposits in blood vessels that can greatly increase the risk of developing cardiovascular disease or experiencing a cardiovascular event. The purpose of this research study is to assess whether lowering of cholesterol blood level can reduce your risk for major cardiovascular events (for example, heart attack or stroke) when evolocumab is taken in addition to current medical therapy as directed by a doctor, which may include a medication for the treatment of abnormal cholesterol blood levels called statins.
Protocol #19-6511, No Longer Enrolling: 11/19/2021
Locations: Memorial Hospital Central;
More information available at ClinicalTrials.gov: NCT03872401
Demonstrate benefit of using the ECG Belt Research System on reducing left ventricular end-systolic volume (LVESV) from baseline to 6 months post-implant compared to standard CRT. ECG Belt arm subjects will be compared with the control arm subjects (combined control arms A and B). A core lab blinded to randomization and follow up status will analyze the echo data and measure LVESV. Demonstrate benefit of using the ECG Belt Research System on reducing left ventricular end-systolic volume (LVESV) from baseline to 6 months post-implant compared to standard CRT. ECG Belt arm subjects will be compared with the control arm subjects (combined control arms A and B). A core lab blinded to randomization and follow up status will analyze the echo data and measure LVESV.
Protocol #19-1703, No Longer Enrolling: 9/29/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03504020
Adult patients with symptomatic clinically significant heart failure and elevated left atrial pressure despite guideline directed medical therapy (GDMT).
Protocol #18-2765, No Longer Enrolling: 1/20/2022
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03088033
You are being asked to participate in this research study because you have been diagnosed with heart failure and you are implanted with a commercially approved Boston Scientific Implantable Cardioverter Defibrillator (ICD) or Cardiac Resynchronization Therapy Defibrillator (CRT-D) device. Inside your device are sensors that monitor your heart failure condition. The purpose of this study is to better understand how sensor readings from your device relate to specific clinical events that you may experience during the time you are in the study. This information may be able to detect when your heart failure is getting worse earlier and with more accuracy. This could help your doctor treat your heart failure timely and with the appropriate treatments.
Protocol #19-6516, No Longer Enrolling: 8/8/2020
Locations: Memorial Hospital Central;
More information available at ClinicalTrials.gov: NCT03579641
Protocol #20-0104, No Longer Enrolling: 6/19/2021
Locations: University of Colorado Hospital;
The SURPOINT COA study is a prospective, multicenter, non-randomized post-market clinical evaluation of the VISITAG SURPOINT™ Module with EPU when used with the STSF/ST catheters in treating subjects with symptomatic PAF who have failed at least one antiarrhythmic drug. A total of 330 subjects will be enrolled at up to 45 sites. Two hundred eighty (280) enrolled subjects will be treated using the STSF catheter with EPU and fifty (50) subjects will be treated with ST catheter. Prior to enrollment, a few sites will be selected to only enroll subjects who will be treated with the ST catheter and the remaining sites will only enroll subjects who will be treated with the STSF catheter. Effectiveness and safety endpoints have been defined, and will be compared to predetermined performance goals. Subjects who sign the SURPOINT COA informed consent are considered enrolled in the study. Enrolled subjects who satisfy all eligibility criteria will then undergo the ablation procedure with the catheter and VISITAG SURPOINT™ Module. After the study ablation procedure, subjects will enter a 3-Month blanking period (Day 0-90). After the Blanking Period, subjects will enter the Evaluation Period (Days 91-365). Subjects having AF recurrence and/or receiving therapeutic interventions during the evaluation period will be considered effectiveness failures (refer to Section 4.1.1 for all effectiveness failure modes). All subjects will undergo follow up visits at defined intervals (refer to Table 5-1 Schedule of Treatments and Evaluations). Subjects complete the SURPOINT COA study after the 12-month follow up visit.
Protocol #19-0003, No Longer Enrolling: 9/29/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03624881
Protocol #19-0105, No Longer Enrolling: 6/9/2021
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT03312751
Randomized, double-blind, placebo-controlled study of ION‑682884 vs. placebo administered by SC injection once every 4 weeks for 120 weeks in patients with ATTR-CM receiving available background SoC. Patients will be stratified at Randomization based on NYHA Classification (I and II vs. III), ATTR mutation status (mutated vs. wild-type), 6MWT (≤ 350 meters vs. > 350 meters), and current treatment with tafamidis (Yes vs. No). Study Drug (ION‑682884 or placebo) will be administered for 120 weeks (Treatment Period) followed by an additional 20 weeks of Post-Treatment Evaluation Period.
Protocol #19-2854, No Longer Enrolling: 10/29/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04136171
Protocol #19-2788, No Longer Enrolling: 7/24/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03165734
While you are taking part in in the study, you will see your doctor as usual. Your doctor will make notes (medical records) about your disease and its treatment as he/she normally would. For the next 5 years, a study coordinator at your doctor’s office will collect information from your doctor’s notes about your medical condition and treatments, including any medication changes.
Protocol #19-6518, No Longer Enrolling: 12/22/2020
Locations: Memorial Hospital Central, Memorial Hospital North;
More information available at ClinicalTrials.gov: NCT04197453
This study is a prospective, randomized, multi-center, global investigation to determine if left atrial appendage closure with the WATCHMAN FLX Device is a reasonable alternative to oral anticoagulation in patients after AF ablation.
Protocol #20-6502, No Longer Enrolling: 7/17/2021
Locations: Medical Center of the Rockies;
More information available at ClinicalTrials.gov: NCT03795298
Protocol #20-1757, No Longer Enrolling: 5/7/2022
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT04409145
Protocol #20-1310, No Longer Enrolling: 9/30/2021
Locations: Childrens Hospital Colorado, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04474223
To establish the safety and effectiveness of the SAPIEN M3 System in subjects with mitral regurgitation (MR) who are at high surgical riskv
Protocol #20-2889, No Longer Enrolling: 4/22/2022
Locations: Medical Center of the Rockies;
More information available at ClinicalTrials.gov: NCT04153292
This study plans to learn more about coronavirus infection in the heart. We wish to investigate whether the coronavirus that causes COVID-19 directly infects heart muscle tissue, and if so, how this might occur. The hope is that once we better understand how this process occurs, that we may be able to develop or utilize drugs to treat this process. Patients are being asked to be in this research study because they have coronavirus causing COVID-19 infection and have signs that is impacting your heart.
Protocol #20-0852, No Longer Enrolling: 3/31/2022
Locations: University of Colorado Hospital;
To determine the mechanisms behind vaccine induced thrombotic thrombocytopenia
Protocol #21-3401, No Longer Enrolling: 4/2/2022
Locations: Department Specific Free Standing Clinic;
Protocol #17-1226, No Longer Enrolling: 4/23/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03221257
- assess the impact of 13 IV infusions of RSLV-132 on cutaneous lupus disease activity using the CLASI activity score. -assess improvement in disease activity using SLEDAI-2K, BILAG-2004 and PGA; - evaluate the immunogenicity of RSLV-132 in subjects with SLE; - assess improvement in tender or swollen joint count; - assess improvement in patient reported outcomes using the FACIT-Fatigue scale; - assess the ability of subjects to reduce oral steroids at Day 169; ? evaluate the safety and tolerability of 22 weeks of RSLV-132 exposure; - assess the proportion of subjects achieving a 50% improvement in CLASI activity score - assess the following exploratory endpoints -- evaluate the impact of RSLV-132 treatment on gene expression profile; -- evaluate the impact of RSLV-132 treatment on autoantibody and complement profiles; -- evaluate the impact of RSLV-132 on serum protein levels; -- assess the impact of RSLV-132 on the CLASI damage score
Protocol #16-0603, No Longer Enrolling: 1/4/2020
Locations: Barbara Davis Center, UCD Barbara Davis Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02660944
-To evaluate the efficacy and dose response of evobrutinib (also referred to as M2951) compared to placebo in reducing disease activity in adult subjects with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard of care (SoC) therapy based on SLE Responder Index (SRI)-4 response at Week 52 in all subjects, or on SRI-6 response at Week 52 in the High Disease Activity (HDA) subgroup, defined as SLE Disease Activity Index 2000 (SLEDAI-2K) !Y 10 -To evaluate the safety of M2951 in subjects with SLE on SoC therapy
Protocol #17-0405, No Longer Enrolling: 1/6/2021
Locations: Barbara Davis Center, UCD Barbara Davis Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02975336
Protocol #17-1792, No Longer Enrolling: 10/1/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03398837
Protocol #17-2000, No Longer Enrolling: 1/6/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03215927
Protocol #18-0489, No Longer Enrolling: 1/4/2020
Locations: Barbara Davis Center, UCD Barbara Davis Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03161483
Protocol #18-0907, No Longer Enrolling: 1/4/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03517722
Protocol #18-2346, No Longer Enrolling: 9/10/2021
Locations: Outpatient CTRC, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03742037
Protocol #19-0027, No Longer Enrolling: 9/29/2021
Locations: Barbara Davis Center;
More information available at ClinicalTrials.gov: NCT03724916
Protocol #19-1717, No Longer Enrolling: 4/11/2020
Locations: Barbara Davis Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03994731
Protocol #19-2533, No Longer Enrolling: 5/13/2021
Locations: Barbara Davis Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04115748
Protocol #19-2534, No Longer Enrolling: 5/13/2021
Locations: Barbara Davis Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04115839
This is a multi-center, randomized, double-blind, placebo-controlled food challenge (DBPCFC) to be conducted in infants or children with confirmed IgE-mediated cow’s milk allergy (CMA), followed by a 7-day open feeding of the experimental formula
Protocol #21-2701, No Longer Enrolling: 3/9/2022
Locations: Childrens Hospital Colorado;
Protocol #17-0713, No Longer Enrolling: 11/14/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03110380
Protocol #13-3028, No Longer Enrolling: 10/22/2019
Locations: University of Colorado Hospital;
Protocol #16-2637, No Longer Enrolling: 5/4/2022
Locations: CTRC-adult, University of Colorado Hospital;
Protocol #17-1512, No Longer Enrolling: 3/8/2022
Locations: University of Colorado Hospital;
The general hypothesis of the proposed pilot study is that older, HIV-infected individuals with a prolonged antiretroviral therapy (ART) treatment history experience an even greater burden of mitochondrial dysfunction, and resulting symptoms of muscle fatigue, physical function impairment, and impaired exercise tolerance compared to HIV-uninfected controls of a similar age and body mass index (BMI).
Protocol #17-2161, No Longer Enrolling: 7/6/2021
Locations: University of Colorado Hospital;
Protocol #17-2431, No Longer Enrolling: 4/6/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03382834
The study is being performed in patients with bacterial pneumonia, an infection in the lung[s] to determine how safe the experimental drug, cefiderocol, is and the amount of cefiderocol that is in blood and lung secretion over time (also known as pharmacokinetics or PK). All participants in this study will receive the study drug.
Protocol #18-1706, No Longer Enrolling: 10/13/2020
Locations: University of Colorado Hospital;
Scientists are looking for ways to effectively clear HIV-1 that stays in the body despite successful antiretroviral treatment. Anti-PD-1 is a type of antibody that may target certain cells called latently infected cells where HIV hides and may improve the body's ability to clear these cells, allowing for the possibility of reducing the amount of HIV that persists (the HIV reservoir). This study will include participants who are diagnosed with HIV-1 and suppressed on their current antiretroviral medications.
Protocol #18-2675, No Longer Enrolling: 11/2/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03787095
Protocol #19-0858, No Longer Enrolling: 3/27/2021
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT03266627
This study will test an experimental drug named GS-6207 (long acting capsid inhibitor) in combination with other HIV medications for the treatment of human immunodeficiency virus (HIV) infection. An experimental drug means that it is not yet approved for the treatment of HIV-1 Infection by the United States Food and Drug Administration (FDA) and your country’s regulatory agency. Other HIV medications included in this study are B/F/TAF (Biktarvy?) and, F/TAF (Descovy?), which are currently approved by the U.S. FDA for the treatment of HIV infection and TAF (VEMLIDY?) and Bictegravir (BIC) which are part of the medication Biktarvy but are not currently approved as a single agent HIV medication by the U.S. FDA. This is a randomized, open label study. Open-label means you and your study doctor will know what study drugs you will be taking. Randomized means the study treatment you take will be chosen by chance (like flipping a coin) to receive one of four study treatments. The randomization for this study is in a 2:2:2:1 ratio. You will have 6 out of 7 chances to receive GS-6207 in combination with other HIV medications and a 1 out of 7 chance to receive B/F/TAF.
Protocol #19-2810, No Longer Enrolling: 9/26/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04143594
Protocol #20-0615, No Longer Enrolling: 9/24/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04315298
Protocol #20-0616, No Longer Enrolling: 1/7/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04292899
Protocol #20-6037, No Longer Enrolling: 8/13/2021
Locations: Greeley Campus, Long's Peak Hospital, Medical Center of the Rockies, Poudre Valley Hospital;
More information available at ClinicalTrials.gov: NCT04326426
The tradipitant therapy is being studied to explore if the administration prevents or treats the cytokine storm and acute respiratory distress syndrome leading to respiratory failure and high mortality in affected patients with COVID-19.
Protocol #20-6506, No Longer Enrolling: 8/12/2021
Locations: Memorial Hospital Central, Memorial Hospital North;
More information available at ClinicalTrials.gov: NCT04326426
To estimate the efficacy, safety, tolerability and reactogenicity of 2 IM doses of AZD1222 compared to placebo for the prevention of COVID-19 in adults. To see if you qualify for the study, please visit this webpage: http://bit.ly/covid19vaccinestudy
Protocol #20-9990, No Longer Enrolling: 2/23/2021
Locations: Greeley Campus, Medical Center of the Rockies, Poudre Valley Hospital;
More information available at ClinicalTrials.gov: NCT04516746
Protocol #19-2746, No Longer Enrolling: 12/2/2021
Locations: Outpatient CTRC, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03931941
In this new study, we will learn if the vaccine can produce an immune response against COVID-19, and if it is safe, in children 5-11 years old. All participants will have the opportunity to receive the COVID-19 study vaccine during their time in the trial.
Protocol #21-2841, No Longer Enrolling: 8/18/2021
Locations: Childrens Hospital Colorado;
Assessment of dapagliflozin vs. placebo to slow the progression of kidney disease in patients with chronic kidney disease (CKD). Participation is expected to last between 1.5-4 years with 9-17 visits during that time. Compensation is provided.
Protocol #17-0412, No Longer Enrolling: 10/1/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03036150
Protocol #17-0678, No Longer Enrolling: 3/31/2022
Locations: Colorado Research Center, Outpatient CTRC, Renal Research Center, University of Colorado Hospital;
Protocol #17-0954, No Longer Enrolling: 5/4/2022
Locations: Colorado Research Center, Renal Research Center, University of Colorado Hospital;
Protocol #17-1327, No Longer Enrolling: 7/8/2021
Locations: Anschutz Health and Wellness, UCD Anschutz Health & Wellness Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03342742
Protocol #17-1812, No Longer Enrolling: 10/18/2019
Locations: University of Colorado Hospital;
MDR-101 is intended to induce mixed lymphohematopoietic chimerism and donor specific immune tolerance in order to preserve transplant kidney function, avert transplant kidney rejection, and eliminate the cumulative and serious side effects associated with IS drugs. Primary Objectives: To evaluate achievement of induction of functional immune tolerance by cellular immunotherapy with MDR-101 in recipients of human leukocyte an tigen (HLA)-matched, living donor kidney transplants. Functional immune tolerance is defined as remaining off of all immunosuppression (IS) drugs for 24 months or more after completion of anti-rejection, IS drug therapy withdrawal with no episodes of biopsy-proven acute rejection (BPAR), de novo donor-specific anti-HLA antibody (dnDSA) development, transplant kidney loss, or subject death. To compare the safety and tolerability of cellular immunotherapy with MDR-101 compared to conventional, standard-of-care (SOC) IS therapy in recipients of HLA-matched, living donor kidney transplants.
Protocol #17-1730, No Longer Enrolling: 6/12/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03363945
A Phase 2, Proof-of-Concept, Randomized, Double-Blinded, Placebo-Controlled Study of ACH-0144471 Treatment for 6 Months in Patients with C3 Glomerulopathy (C3G)
Protocol #17-2178, No Longer Enrolling: 5/28/2021
Locations: Childrens Hospital Colorado, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03369236
Protocol #17-2336, No Longer Enrolling: 4/29/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02683889
This is a 12 week observational study of cognitive and blood vessel functioning 2 weeks and 12 weeks after an acute kidney injury.
Protocol #18-0654, No Longer Enrolling: 4/6/2021
Locations: University of Colorado Hospital;
The study is a multicenter, prospective, double-blind, randomized, placebo-controlled, pivotal registration study. The Sponsor, Investigators and patients will all be blinded to study drug assignment. Patients in this study are at risk for requiring dialysis in the first week following transplantation of a kidney from a deceased donor and have early clinical indication of DGF based on poor renal function post-transplantation. Patients who fulfill all other eligibility criteria will be randomized in a 1:1 fashion to receive 2 mg/kg ANG-3777 or placebo (normal saline). Primary Objective: ? To demonstrate the safety and efficacy of ANG-3777 in reducing the severity of delayed graft function (DGF) in recipients at high risk of DGF after receiving a deceased donor renal allograft with DGF Secondary Objectives: ? To demonstrate the efficacy of ANG-3777 in optimizing renal function in recipients of a deceased donor renal allograft with DGF ? To demonstrate the efficacy of ANG-3777 in reducing length of hospital stay in recipients of a deceased donor renal allograft with DGF
Protocol #16-1038, No Longer Enrolling: 10/2/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02474667
Protocol #17-0275, No Longer Enrolling: 10/1/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02547220
This is an international, multicenter trial. Participants will be given either active study drug or placebo and will be followed for a period of 2 years.
Protocol #18-1842, No Longer Enrolling: 9/22/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03523728
Study CCFZ533A2201 is a randomized, 12-month, active-controlled, partially-blinded, multicenter, dose range finding study to evaluate the efficacy, safety, tolerability, PK and PD of CFZ533 in 2 different cohorts: -In adult de novo kidney transplant recipients, CFZ533 in combination with MMF and corticosteroids as compared to standard of care comprised of tacrolimus, MMF and corticosteroids. -In a maintenance kidney transplant population (6-24 months post-transplant), CFZ533 in combination with MMF with or without corticosteroids, compared to a standard of care control arm of tacrolimus and MMF with or without corticosteroids. COHORT 1: Primary Objective(s) -To demonstrate that CFZ533 600 mg or 300 mg bi-weekly (Q2W), subcutaneous (SC), are non-inferior to a tacrolimus-based regimen with respect to the proportion of patients who experience the composite efficacy failure event (Biopsy proven acute rejection (BPAR), Graft Loss or Death) over 12 months post-transplantation. Key secondary objective: -To demonstrate that CFZ533 600 mg or 300 mg Q2W SC are superior to a tacrolimus-based regimen with respect to the mean estimated glomerular filtration rate (eGFR) at 12 months post-transplantation. COHORT 2: Primary Objective(s) -To demonstrate that CFZ533 450 mg Q2W SC is non-inferior to a tacrolimus-based regimen with respect to the proportion of patients who experience the composite event (BPAR, Graft Loss or Death) over 12 months post conversion. Key secondary objective: -To demonstrate that CFZ533 450 mg Q2W SC is superior to a tacrolimus-based regimen with respect to the mean change in eGFR from baseline to 12 months post conversion.
Protocol #18-2117, No Longer Enrolling: 6/12/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03663335
Protocol #18-2337, No Longer Enrolling: 2/15/2022
Locations: Childrens Hospital Colorado;
Evaluation of safety, efficacy and immunosuppression (IS) therapy following FCR001 cell therapy after kidney transplant vs. standard of care. FCR001 is a novel, cryopreserved allogeneic somatic cell therapy, derived from mobilized peripheral blood mononuclear cells from the same donor as the allograft, and containing hematopoietic progenitor cells, facilitating cells and alpha beta T cells. The rationale is to establish durable chimerism and donor-specific tolerance in the recipient enabling freedom from chronic IS and its associated toxicities. Primary Objective: To evaluate the proportion of FCR001 recipients who are free from IS, without biopsy-proven acute rejection (BPAR), at 24 months posttransplant. Key Secondary Objective: To evaluate the change in renal function (estimated glomerular filtration rate [eGFR] by Modification of Diet in Renal Disease (MDRD4) from post-transplant baseline (Month 1) to Month 24 in FCR001 recipients.
Protocol #19-1299, No Longer Enrolling: 9/30/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03995901
Protocol #17-2311, No Longer Enrolling: 10/21/2020
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT04156204
Protocol #18-0225, No Longer Enrolling: 3/26/2020
Locations: Childrens Hospital Colorado;
Protocol #18-2100, No Longer Enrolling: 8/1/2020
Locations: Childrens Hospital Colorado;
Protocol #17-2378, No Longer Enrolling: 2/20/2021
Locations: Childrens Hospital Colorado;
Protocol #18-1723, No Longer Enrolling: 6/24/2020
Locations: Childrens Hospital Colorado;
Each study subject will be randomized to receive either study drug or a placebo for 6 months. Neither the subject nor the study staff will know which treatment was given until after the study has finished. Study subjects will be monitored every 2 weeks for the first month, then less frequently as the study progresses. The total length of the study is about 8 months.
Protocol #19-2819, No Longer Enrolling: 9/25/2020
Locations: Renal Research Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03373461
Protocol #17-0573, No Longer Enrolling: 6/4/2021
Locations: Childrens Hospital Colorado;
Protocol #19-2333, No Longer Enrolling: 2/9/2021
Locations: Childrens Hospital Colorado;
Each study subject will start with 12 weeks of treatment of MMF. After the 12 weeks of MMF, the subjects with an inadequate renal response may be randomized to one of the BMS-986165 treatment groups or placebo as add-on treatment to MMF. Subjects will be monitored and evaluated every 4 weeks for 52 weeks. Neither the subject or study staff will know which treatment was given until after the study has finished.
Protocol #19-2904, No Longer Enrolling: 7/13/2021
Locations: Renal Research Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03943147
This study plans to learn more about the effects of an investigational new drug (DMXB-A) and its effects on obesity. The study drug has similar effects to nicotine. Since nicotine has been found to effect appetite, we are interested in studying the effects of the study drug, which has similarities to nicotine, on how your brain responds to such things as pictures of food. This study drug has not been approved by the Food and Drug Administration (FDA), and is considered experimental. This research study plans to examine the effects of an investigational new drug on neuronal, physiological, and behavioral mechanisms of obesity in the general population.
Protocol #15-0650, No Longer Enrolling: 12/31/2021
Locations: Outpatient CTRC, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02458313
Protocol #17-0373, No Longer Enrolling: 6/24/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03013543
The goal of this study is to learn more about how brain function drives binge eating, a condition where individuals eat unhealthy large amounts of food
Protocol #16-2658, No Longer Enrolling: 10/1/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03393039
Protocol #18-0487, No Longer Enrolling: 2/27/2020
Locations: Anschutz Health and Wellness, UCD Anschutz Health & Wellness Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03571048
In this study we will be evaluating how your brain responds to food images, as well as how your behaviors and hormones change with a 12-week resistance training intervention.
Protocol #18-1298, No Longer Enrolling: 1/26/2022
Locations: Anschutz Health and Wellness, UCD Anschutz Health & Wellness Center, University of Colorado Hospital;
What will be asked of you: Eligible participants will be asked to follow a lifestyle program for a total of 4 months, complete one (virtual) assessment, and complete questionnaires at the beginning and end of the study. All participants will receive: - A Freestyle Libre 2 continuous blood glucose meter and supplies for 3 months - A Fitbit? activity monitor - A treatment manual and diary The goal is to study a non-medication treatment for adults newly diagnosed with Type 2 Diabetes (T2D) that uses a lifestyle program and continuous glucose monitoring to see if this reduces or prevents the need for diabetes medications.
Protocol #20-2470, No Longer Enrolling: 12/4/2021
Locations: Department Specific Free Standing Clinic;
The primary objectives of this study are: - to compare the efficacy of basiliximab induction, ASKP1240, mycophenolate mofetil [MMF], and steroids to the standard of care immunosuppressive regimen (basiliximab induction + tacrolimus + MMF + steroids) [CNI avoidance]. - to compare the efficacy of basiliximab induction, ASKP1240, tacrolimus, and steroids to the standard of care immunosuppressive regimen (basiliximab induction + tacrolimus + MMF + steroids) [CNI minimization- MMF avoidance]. The secondary objectives of this study are: - to compare the safety of the experimental arms to the standard of care arm. -to evaluate the long term safety and tolerability of ASKP1240 administration in subjects in the Long Term Extension (LTE) period of the study.
Protocol #13-0061, No Longer Enrolling: 10/1/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT01780844
This study plans to learn more about breast cancer in young women, including the biology of the disease and young women's experiences with it. We aim to use this information to improve the care and information available for young women with breast cancer.
Protocol #08-1222, No Longer Enrolling: 2/12/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT01468246
Protocol #07-0354, No Longer Enrolling: 2/13/2021
;
Protocol #10-1084, No Longer Enrolling: 10/2/2021
;
Protocol #11-1248, No Longer Enrolling: 10/24/2019
;
Protocol #11-1640, No Longer Enrolling: 6/30/2021
;
Protocol #12-0144, No Longer Enrolling: 1/6/2021
;
Protocol #12-1525, No Longer Enrolling: 11/1/2019
;
Protocol #12-1557, No Longer Enrolling: 11/1/2019
;
Protocol #13-0101, No Longer Enrolling: 11/1/2019
;
Protocol #13-2952, No Longer Enrolling: 10/24/2019
;
Protocol #14-1971, No Longer Enrolling: 1/6/2021
;
Protocol #14-0712, No Longer Enrolling: 6/30/2021
;
Protocol #14-0884, No Longer Enrolling: 10/24/2019
;
Protocol #15-1397, No Longer Enrolling: 11/23/2019
Locations: University of Colorado Hospital;
Protocol #15-1676, No Longer Enrolling: 10/22/2019
;
Protocol #14-0654, No Longer Enrolling: 10/2/2021
;
Protocol #15-1621, No Longer Enrolling: 3/10/2020
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02992015
Protocol #14-2369, No Longer Enrolling: 11/3/2021
;
Protocol #15-2069, No Longer Enrolling: 10/1/2019
Locations: University of Colorado Hospital;
Protocol #15-2078, No Longer Enrolling: 1/17/2020
Locations: Greeley Hospital, Harmony Campus, Medical Center of the Rockies, Poudre Valley Hospital, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02308085
Protocol #15-2279, No Longer Enrolling: 11/28/2019
;
In this study we are looking at how the brain works in people who have dystonia compared to those who don't have dystonia. This study will use magnetic resonance imaging (MRI), magnetoencephalography (MEG), and Electroencephalography (EEG) to see how the brain reacts while resting and doing a finger-tapping task. Aim 1: A second level contrast between Primary Focal Dystonia (PFD) and Healthy Controls (HC) of the statistical parametric maps of correlation coefficients at rest and during a tapping motor task Aim 2: the strength of correlation between basal ganglia motor network functional connectivity measures and total PFD clinical assessment scale scores
Protocol #12-0289, No Longer Enrolling: 2/4/2021
Locations: Colorado Research Center, Department Specific Free Standing Clinic, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT01761903
Protocol #15-0963, No Longer Enrolling: 10/22/2019
;
Protocol #15-1187, No Longer Enrolling: 10/22/2019
;
Protocol #15-1106, No Longer Enrolling: 10/22/2019
;
Protocol #16-1023, No Longer Enrolling: 11/7/2019
Locations: University of Colorado Hospital;
Protocol #16-0705, No Longer Enrolling: 9/22/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02779751
Protocol #16-0225, No Longer Enrolling: 6/29/2021
;
More information available at ClinicalTrials.gov: NCT02596997
Protocol #16-0907, No Longer Enrolling: 11/23/2019
Locations: Childrens Hospital Colorado;
Protocol #16-1082, No Longer Enrolling: 10/18/2019
Locations: University of Colorado Hospital;
To collect archival tissues and validated clinical history of deceased Lung cancer patients & deposit them into the NCI SPORE biobank
Protocol #15-1294, No Longer Enrolling: 11/23/2019
Locations: Department Specific Free Standing Clinic, University of Colorado Cancer Center;
Protocol #15-2393, No Longer Enrolling: 5/22/2020
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02484443
Protocol #14-2270, No Longer Enrolling: 10/1/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02378883
Protocol #15-0461, No Longer Enrolling: 11/9/2019
Locations: Boulder Health Center, Cherry Creek Medical Center, Greeley Hospital, Harmony Campus, Lone Tree Medical Center, Longs Peak Hospital, Medical Center of the Rockies, Memorial Hospital Central, Memorial Hospital North, Pikes Peak Regional Hospital, Poudre Valley Hospital, Steadman Hawkins Clinic - Denver, UCHealth Internal Medical Clinic - Lowry, UCHealth Stapleton Medical Center, University of Colorado Hospital;
1. To determine which pharmaceutical therapy is most effective and causes the fewest side effects in CSPN. 2. To determine which drug has the fewest and which has the most side effects.
Protocol #14-2157, No Longer Enrolling: 10/1/2019
Locations: University of Colorado Hospital;
1. To assess the effect of vocal folds augmentation with long acting calcium hydroxyapatite paste on the quality of voice in PD subjects. 2. To assess the effect of vocal folds augmentation with long acting calcium hydroxyapatite paste on structural and functional parameters of the larynx measured on videostroboscopic recordings assessing glottic closure time and supraglottic constriction. 3. Assess the duration of the long term treatment effect.
Protocol #16-1127, No Longer Enrolling: 5/11/2021
Locations: University of Colorado Hospital;
Protocol #16-1285, No Longer Enrolling: 4/15/2020
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02304458
Protocol #16-1240, No Longer Enrolling: 3/10/2021
Locations: Greeley Campus, Harmony Campus, Highlands Ranch Hospital, Lone Tree Medical Center, Medical Center of the Rockies, Memorial Hospital Central, Memorial Hospital North, Poudre Valley Hospital, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02750826
To obtain whole blood specimens from pregnant subjects to be used for research and development and clinical validation studies of prenatal assays.
Protocol #16-0911, No Longer Enrolling: 1/21/2021
Locations: Childrens Hospital Colorado, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02430584
Protocol #16-0908, No Longer Enrolling: 11/23/2019
Locations: University of Colorado Hospital;
Protocol #16-0895, No Longer Enrolling: 11/23/2019
Locations: University of Colorado Hospital;
Protocol #16-0932, No Longer Enrolling: 11/19/2020
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02868268
Protocol #16-1541, No Longer Enrolling: 11/20/2019
Locations: University of Colorado Hospital;
Protocol #16-1496, No Longer Enrolling: 11/23/2019
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT03482154
Protocol #11-0909, No Longer Enrolling: 7/6/2021
;
Protocol #16-1714, No Longer Enrolling: 11/23/2019
Locations: University of Colorado Hospital;
Protocol #15-1309, No Longer Enrolling: 12/27/2019
Locations: CTRC-adult, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02544321
Protocol #15-1348, No Longer Enrolling: 10/1/2019
;
More information available at ClinicalTrials.gov: NCT02208440
Protocol #16-1782, No Longer Enrolling: 10/8/2020
Locations: University of Colorado Hospital;
Protocol #16-2525, No Longer Enrolling: 11/23/2019
Locations: University of Colorado Hospital;
Protocol #16-1884, No Longer Enrolling: 10/22/2019
Locations: University of Colorado Hospital;
Protocol #16-1983, No Longer Enrolling: 10/22/2019
Locations: University of Colorado Hospital;
Protocol #11-0693, No Longer Enrolling: 12/27/2019
Locations: CTRC-adult, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT01813929
Protocol #06-0062, No Longer Enrolling: 10/1/2019
Locations: CTRC-adult, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT01793909
Protocol #13-2015, No Longer Enrolling: 10/4/2019
Locations: CTRC-adult;
More information available at ClinicalTrials.gov: NCT01951339
Protocol #16-2276, No Longer Enrolling: 11/23/2019
;
Protocol #16-0868, No Longer Enrolling: 11/23/2019
Locations: University of Colorado Hospital;
Protocol #16-2437, No Longer Enrolling: 12/5/2020
Locations: Greeley Campus, Harmony Campus, Highlands Ranch Hospital, Lone Tree Medical Center, Medical Center of the Rockies, Memorial Hospital Central, Memorial Hospital North, Poudre Valley Hospital, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02927249
Protocol #16-2448, No Longer Enrolling: 9/30/2020
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT03392142
Protocol #16-2487, No Longer Enrolling: 10/24/2019
Locations: University of Colorado Hospital;
Protocol #16-2594, No Longer Enrolling: 8/19/2021
Locations: Greeley Campus, Harmony Campus, Highlands Ranch Hospital, Lone Tree Medical Center, Medical Center of the Rockies, Memorial Hospital Central, Memorial Hospital North, Poudre Valley Hospital, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02954874
Protocol #16-2160, No Longer Enrolling: 11/23/2019
Locations: Rocky Mountain Regional VA Medical Center, University of Colorado Hospital;
Protocol #16-2755, No Longer Enrolling: 10/22/2019
Locations: University of Colorado Hospital;
Protocol #15-2242, No Longer Enrolling: 1/15/2021
;
Protocol #15-2466, No Longer Enrolling: 3/10/2021
;
Protocol #16-2636, No Longer Enrolling: 11/26/2019
Locations: University of Colorado Hospital;
Protocol #17-0192, No Longer Enrolling: 10/1/2019
Locations: University of Colorado Hospital;
Protocol #16-2228, No Longer Enrolling: 11/26/2019
Locations: University of Colorado Hospital;
Protocol #14-1505, No Longer Enrolling: 10/4/2019
Locations: University of Colorado Hospital;
This study plans to learn more about immune responses in intestinal (gut) tissue in people with human immunodeficiency virus (HIV) infection. This study will determine whether change in the composition of gut bacteria in HIV infected individuals is related to a high prevalence of chronic gut inflammation and metabolic disease. The investigators will also investigate immune-modulatory properties of specific bacteria that correlate with disease both by characterizing which functional genes are selected for in their genomes and by stimulating immune cells isolated from blood and gut tissue with bacterial isolates. This work will establish whether gain/loss of bacterial drivers/suppressors of information in the gut contributes to metabolic disease in HIV-infected individuals.
Protocol #14-1595, No Longer Enrolling: 10/4/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02258685
The investigators hypothesize that neutrophils and monocytes developed under the influence of Interferon- gamma-1b (IFN-gamma-1b, Actimmune(R) in vivo will display enhanced function across a broad range of activities related in large part to the transcriptional activation effects of this cytokine. The investigators will evaluate the effects of IFN-? in healthy human subjects in vivo on gene expression, biologic activity markers, and functional activity of myeloid cells in single dose studies and in steady state studies.
Protocol #15-1643, No Longer Enrolling: 10/1/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02609932
Protocol #13-2122, No Longer Enrolling: 4/6/2021
Locations: University of Colorado Hospital;
The primary objective of this proposal is to compare a moderate or high intensity exercise intervention to improve physical function in persons aging with Human Immunodeficiency Virus (HIV).
Protocol #14-2207, No Longer Enrolling: 10/4/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02404792
Protocol #16-1564, No Longer Enrolling: 12/17/2019
;
The primary goal of this research is to find out if exercise that causes the loss of calcium from the blood, possibly through the sweat, also causes the release of calcium from the bones.
Protocol #15-0250, No Longer Enrolling: 5/20/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02468817
1. To establish the relationship between exposure to certain female factors (e.g. contraceptive, menstrual, pregnancy and sexual history) and the presence of serum RA-related autoimmunity and/or RA-related immunologic factors in subjects with RA, subjects at-risk for RA, and control subjects. These evaluations will include baseline and longitudinal studies to determine incident development of RA-related autoimmunity. 2. To determine the prevalence of RA-related biomarkers, such as Abs and inflammatory cytokines, in the lower female genital tract in women with RA, women at-risk for RA, and controls. These evaluations will include baseline and longitudinal studies to determine incident development of RA-related autoimmunity at the CV mucosa. 3. To evaluate microbial communities in the lower female genital tract of women with RA, women at-risk for RA, and control subjects. These evaluations will include baseline and longitudinal studies of microbiota as well as comparison to serum and CV biomarkers. 4. To simultaneously compare RA-related Abs and immunologic biomarkers in the female genital tract and serum in women with RA, women at-risk for RA and control subjects. These evaluations include cross-sectional and longitudinal studies to determine evolution over time at each site (CV fluid and serum) to determine incident development of RA-related autoimmunity. 5. To demonstrate specific immunologic mechanisms of RA-related Ab generation in the cervical and uterine mucosa associated with systemic or mucosal RA-related Abs in women who had previously obtained and stored cervical or uterine tissue. 6. To compare the performance of self-collected and investigator-collected CV samples for detection of mucosal immunity and microbiota.
Protocol #14-1751, No Longer Enrolling: 10/4/2019
Locations: University of Colorado Hospital;
The goal of this study is to determine whether the use of the PSS with Truvada will vary the drug concentrations of FTC/TDF.
Protocol #16-1478, No Longer Enrolling: 10/16/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02968576
This study seeks to improve our understanding of worry among adolescents.
Protocol #15-1593, No Longer Enrolling: 1/14/2022
;
The primary purpose of the research study is to determine the safety and tolerability of the study drug (Metformin or placebo) when given to subjects with ADPKD (Autosomal Dominant Polycystic Kidney Disease).
Protocol #16-0802, No Longer Enrolling: 7/6/2021
Locations: Department Specific Free Standing Clinic, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02903511
To research the effects of an investigational drug on exercise capacity and blood vessel function.
Protocol #10-1393, No Longer Enrolling: 5/18/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT01580813
The purpose of this study is to compare two medications, natalizumab and fingolimod, used in the treatment of multiple sclerosis (MS) through a variety of previously validated patient reported outcomes (PROs).
Protocol #13-2767, No Longer Enrolling: 7/6/2021
Locations: University of Colorado Hospital;
Protocol #16-0479, No Longer Enrolling: 10/2/2021
Locations: Denver Health and Hospital Authority, University of Colorado Hospital;
The overall goal of this pilot project is to take the first steps toward developing translational methods to investigate links between changes in energy flux and the circadian system in human tissues.
Protocol #15-1570, No Longer Enrolling: 12/27/2019
Locations: CTRC-adult, Denver Health Medical Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02809482
The goal of this study is to determine if a specific experimental brain stimulation technique can be used as a non-invasive way to reduce cigarette cravings in current smokers.
Protocol #15-1016, No Longer Enrolling: 6/30/2021
;
More information available at ClinicalTrials.gov: NCT02590640
The purpose of the research study "Heart Sounds at Home" is for pregnant SSA or SSA/SSB (Sjogren syndrome B) antibody positive mothers to use a Doppler fetal heart rate monitor to detect abnormal heart rates and rhythms in their babies before they are born.
Protocol #13-1879, No Longer Enrolling: 5/1/2021
;
More information available at ClinicalTrials.gov: NCT02920346
Determine the efficacy of the EnteroTracker String Test (EST)for monitoring inflammation in the esophagus. Compare analysis of the EST to biopises taken during an upper endoscopy.
Protocol #07-0223, No Longer Enrolling: 12/31/2019
Locations: Childrens Hospital Colorado, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02008903
Protocol #16-1787, No Longer Enrolling: 6/30/2021
;
This research plans to learn more about the use of telemedicine as a means of providing therapy to children who have a cochlear implant(s). While Auditory-Verbal Therapy has typically been delivered in person, many people are starting to access therapy over the internet. We are conducting this research to determine if the outcomes of therapy are the same when AVT is delivered in person and via telemedicine.
Protocol #12-1103, No Longer Enrolling: 9/21/2021
;
Protocol #13-0328, No Longer Enrolling: 10/2/2021
;
More information available at ClinicalTrials.gov: NCT02209636
This research study will compare blood vessel function in healthy adults to adults with two different types of kidney disease. The testing visit will include non-invasive testing of blood vessel function and collection of blood and cells from an IV.
Protocol #15-0869, No Longer Enrolling: 7/6/2021
;
Protocol #16-2747, No Longer Enrolling: 3/10/2020
Locations: Childrens Hospital Colorado;
Protocol #17-0486, No Longer Enrolling: 1/22/2021
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02717507
Protocol #17-0222, No Longer Enrolling: 3/15/2022
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT03347526
Protocol #17-0763, No Longer Enrolling: 11/26/2019
Locations: University of Colorado Hospital;
Protocol #16-0604, No Longer Enrolling: 10/1/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02260934
Protocol #14-0381, No Longer Enrolling: 10/9/2020
Locations: University of Colorado Hospital;
Protocol #15-1799, No Longer Enrolling: 12/28/2019
Locations: CTRC-adult, University of Colorado Hospital;
Protocol #15-0541, No Longer Enrolling: 12/27/2019
Locations: CTRC-adult, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02502071
Protocol #14-0193, No Longer Enrolling: 5/20/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02122198
Protocol #15-0933, No Longer Enrolling: 5/22/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02542150
Protocol #14-0774, No Longer Enrolling: 5/20/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02307877
Protocol #15-0520, No Longer Enrolling: 4/6/2021
Locations: University of Colorado Hospital;
Protocol #17-0365, No Longer Enrolling: 10/22/2019
Locations: University of Colorado Hospital;
Protocol #15-0123, No Longer Enrolling: 5/20/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02588287
Protocol #15-1854, No Longer Enrolling: 9/18/2020
Locations: University of Colorado Hospital;
Protocol #17-0666, No Longer Enrolling: 11/7/2019
Locations: Childrens Hospital Colorado;
Protocol #17-0722, No Longer Enrolling: 10/1/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02989610
Protocol #16-6086, No Longer Enrolling: 7/28/2021
Locations: Greeley Campus, Harmony Campus, Medical Center of the Rockies, Poudre Valley Hospital;
More information available at ClinicalTrials.gov: NCT02713867
Protocol #17-0215, No Longer Enrolling: 10/1/2019
Locations: University of Colorado Hospital;
Protocol #17-0812, No Longer Enrolling: 6/24/2020
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02777021
Protocol #17-6150, No Longer Enrolling: 5/20/2020
Locations: Memorial Hospital Central;
More information available at ClinicalTrials.gov: NCT02960854
Protocol #16-2568, No Longer Enrolling: 5/28/2021
Locations: University of Colorado Hospital;
Protocol #16-1954, No Longer Enrolling: 5/28/2021
Locations: University of Colorado Hospital;
Protocol #17-1041, No Longer Enrolling: 11/7/2019
Locations: University of Colorado Hospital;
Protocol #17-0784, No Longer Enrolling: 10/5/2019
Locations: University of Colorado Hospital;
The primary objective of this registry is to determine the procedure related mortality associated with the use of the Angiovac device. This is a FDA approved device, being used in clinical practice for the removal of fresh, soft thrombi or emboli during extracorporeal bypass for up to 6 hours.
Protocol #15-1608, No Longer Enrolling: 11/6/2020
Locations: University of Colorado Hospital;
Protocol #17-1222, No Longer Enrolling: 11/26/2019
Locations: University of Colorado Hospital;
Protocol #17-0734, No Longer Enrolling: 10/1/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03160898
Protocol #17-1307, No Longer Enrolling: 11/26/2019
Locations: University of Colorado Hospital;
Protocol #16-1909, No Longer Enrolling: 12/2/2021
;
Protocol #17-1136, No Longer Enrolling: 10/18/2019
Locations: University of Colorado Hospital;
Protocol #16-1748, No Longer Enrolling: 5/2/2020
Locations: University of Colorado Hospital;
Protocol #16-1074, No Longer Enrolling: 11/14/2019
Locations: University of Colorado Hospital;
Protocol #17-1336, No Longer Enrolling: 11/28/2019
Locations: University of Colorado Hospital;
Protocol #17-0850, No Longer Enrolling: 11/1/2019
Locations: University of Colorado Hospital;
Protocol #16-0328, No Longer Enrolling: 6/15/2021
Locations: Childrens Hospital Colorado, CTRC Inpatient, University of Colorado Hospital;
Protocol #15-1412, No Longer Enrolling: 1/6/2021
Locations: University of Colorado Hospital;
Protocol #17-1004, No Longer Enrolling: 11/7/2019
Locations: University of Colorado Hospital;
Protocol #17-1267, No Longer Enrolling: 11/2/2019
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02562235
Protocol #16-2414, No Longer Enrolling: 10/22/2019
Locations: University of Colorado Hospital;
Protocol #17-1314, No Longer Enrolling: 9/10/2021
;
Protocol #17-6191, No Longer Enrolling: 3/3/2021
Locations: Medical Center of the Rockies;
Accuracy of the software will be evaluated through case review. The cases entered into the Lifeboard software will be compared to the paper trauma flow sheet. Research staff will be comparing what is entered into the software on the tablet against the trauma flow sheet for each case.
Protocol #UCH14-1326, No Longer Enrolling: 1/6/2021
Locations: Medical Center of the Rockies;
Protocol #UCH11-0510, No Longer Enrolling: 10/1/2019
Locations: Memorial Hospital Central;
Protocol #UCH11-0716, No Longer Enrolling: 10/1/2019
Locations: Memorial Hospital Central;
Protocol #UCH14-0104, No Longer Enrolling: 5/19/2020
Locations: Memorial Hospital Central;
Protocol #UCH07-0207, No Longer Enrolling: 10/1/2019
Locations: Memorial Hospital Central;
Protocol #UCH10-0821, No Longer Enrolling: 10/1/2019
Locations: Memorial Hospital Central;
Protocol #UCH11-1023, No Longer Enrolling: 10/1/2019
Locations: Memorial Hospital Central;
Protocol #UCH09-0308, No Longer Enrolling: 10/1/2019
Locations: Memorial Hospital Central;
Protocol #UCH11-0715, No Longer Enrolling: 10/1/2019
Locations: Memorial Hospital Central;
Protocol #17-0380, No Longer Enrolling: 11/1/2019
Locations: Memorial Hospital Central, Memorial Hospital North;
Protocol #UCH09-1018, No Longer Enrolling: 10/1/2019
Locations: Memorial Hospital Central;
Protocol #UCH06-0629, No Longer Enrolling: 10/1/2019
Locations: Memorial Hospital Central;
Protocol #UCH07-0623, No Longer Enrolling: 10/1/2019
Locations: Memorial Hospital Central;
Protocol #UCH06-0730, No Longer Enrolling: 10/1/2019
Locations: Memorial Hospital Central;
Structure: This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study. Duration: Patients will be enrolled in the study for up to 16 weeks, with up to a 4-week screening period and a 12-week treatment period. Study Treatment: The investigational product is AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]), which is titrated over a 2-week period to d6-DM 42.63 mg/Q 4.9 mg (AVP-786-42.63/4.9) twice daily (BID). Control: Placebo capsules appearing identical to study medication will be used as control. Randomization: Eligible patients will be randomized into the study to receive AVP-786 or placebo. Dose Regimen:
Protocol #17-6198, No Longer Enrolling: 3/24/2021
Locations: Medical Center of the Rockies;
More information available at ClinicalTrials.gov: NCT03095066
Protocol #UCH02-1026, No Longer Enrolling: 10/1/2019
Locations: Memorial Hospital Central;
Protocol #17-6199, No Longer Enrolling: 5/19/2020
Locations: Memorial Hospital Central;
More information available at ClinicalTrials.gov: NCT03095006
Protocol #13-3034, No Longer Enrolling: 4/2/2021
Locations: University of Colorado Hospital;
Six month intervention of ovarian hormone supression This research study plans to learn more about the role of female sex hormones on fat and the gut microbiome (or the organisms that are in your digestive tract).
Protocol #17-1869, No Longer Enrolling: 8/19/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03396978
Protocol #16-1551, No Longer Enrolling: 10/1/2019
Locations: University of Colorado Hospital;
To compare PFS between ribociclib in combination with fulvestrant to placebo in combination with fulvestrant among postmenopausal women with HR+, HER2-negative advanced breast cancer who received no or only one prior endocrine treatment for advanced disease
Protocol #15-6019, No Longer Enrolling: 1/29/2020
Locations: Greeley Hospital, Harmony Campus, Medical Center of the Rockies, Poudre Valley Hospital;
More information available at ClinicalTrials.gov: NCT02422615
Protocol #16-6057, No Longer Enrolling: 10/1/2019
Locations: Greeley Hospital, Harmony Campus, Medical Center of the Rockies, Poudre Valley Hospital;
Protocol #15-6038, No Longer Enrolling: 5/3/2022
Locations: Greeley Campus, Harmony Campus, Medical Center of the Rockies, Poudre Valley Hospital;
More information available at ClinicalTrials.gov: NCT02492711
Protocol #UCH12-1142, No Longer Enrolling: 5/20/2020
;
Protocol #UCH13-1272, No Longer Enrolling: 5/20/2020
;
Protocol #15-6021, No Longer Enrolling: 1/6/2021
Locations: Memorial Hospital Central;
Protocol #UCH04-680, No Longer Enrolling: 5/20/2020
Locations: Greeley Campus, Harmony Campus, Medical Center of the Rockies, Poudre Valley Hospital;
More information available at ClinicalTrials.gov: NCT00975676
Protocol #UCH11-1101, No Longer Enrolling: 2/19/2022
Locations: Harmony Campus;
Protocol #UCH13-1260, No Longer Enrolling: 11/7/2019
Locations: Greeley Hospital, Harmony Campus, Medical Center of the Rockies, Poudre Valley Hospital;
Protocol #16-0179, No Longer Enrolling: 5/4/2022
Locations: Childrens Hospital Colorado, Denver Health and Hospital Authority, Poudre Valley Hospital, University of Colorado Hospital;
Compassionate use of Lorcaserin in Dravet Syndrome
Protocol #14-2440, No Longer Enrolling: 10/1/2019
Locations: Childrens Hospital Colorado;
The primary aim of this study is to determine rates of stroke for BCVI overall and by grade of injury and predictors of BCVI related stroke formation.
Protocol #18-6029, No Longer Enrolling: 4/13/2022
Locations: Medical Center of the Rockies;
Protocol #17-6220, No Longer Enrolling: 5/20/2020
Locations: Memorial Hospital Central;
Protocol #18-6038, No Longer Enrolling: 5/20/2020
Locations: Memorial Hospital Central;
Protocol #18-0524, No Longer Enrolling: 7/31/2021
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02845596
Protocol #16-0996, No Longer Enrolling: 10/1/2019
Locations: University of Colorado Hospital;
Protocol #13-2415, No Longer Enrolling: 5/2/2020
;
Protocol #18-0834, No Longer Enrolling: 3/2/2021
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT03475212
Protocol #15-2421, No Longer Enrolling: 10/1/2019
Locations: Childrens Hospital Colorado;
Protocol #18-0947, No Longer Enrolling: 4/18/2020
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT03387020
Protocol #18-1073, No Longer Enrolling: 11/28/2019
Locations: University of Colorado Hospital;
Protocol #18-1095, No Longer Enrolling: 4/7/2020
Locations: Memorial Hospital Central, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03403751
Protocol #18-1031, No Longer Enrolling: 10/31/2019
Locations: University of Colorado Hospital;
Protocol #18-1096, No Longer Enrolling: 10/22/2019
Locations: University of Colorado Hospital;
Protocol #18-1143, No Longer Enrolling: 10/22/2019
Locations: University of Colorado Hospital;
Protocol #18-0795, No Longer Enrolling: 11/1/2019
Locations: Childrens Hospital Colorado, University of Colorado Hospital;
Protocol #18-1176, No Longer Enrolling: 10/22/2019
Locations: University of Colorado Hospital;
Protocol #18-1227, No Longer Enrolling: 11/28/2019
Locations: University of Colorado Hospital;
Protocol #18-1251, No Longer Enrolling: 11/7/2019
Locations: University of Colorado Hospital;
Assess the safety and potential efficacy of CLBS03 to modify the T1DM disease course, including preservation of a-cell function and improvements in measures of disease severity, as compared with placebo, in adolescents with recent onset T1DM.
Protocol #16-0905, No Longer Enrolling: 3/23/2022
Locations: Barbara Davis Center, UCD Barbara Davis Center;
Protocol #18-1240, No Longer Enrolling: 11/28/2019
Locations: Childrens Hospital Colorado, University of Colorado Hospital;
Protocol #18-1123, No Longer Enrolling: 11/28/2019
Locations: University of Colorado Hospital;
Protocol #18-1084, No Longer Enrolling: 11/28/2019
Locations: University of Colorado Hospital;
Protocol #13-3192, No Longer Enrolling: 9/10/2021
Locations: Adult Infectious Disease Clinical Trials Center;
More information available at ClinicalTrials.gov: NCT02114333
Protocol #18-1177, No Longer Enrolling: 10/22/2019
Locations: University of Colorado Hospital;
Protocol #18-2184, No Longer Enrolling: 10/31/2019
Locations: Lone Tree Medical Center, University of Colorado Hospital;
Protocol #07-0084, No Longer Enrolling: 10/22/2019
Locations: University of Colorado Hospital;
Protocol #17-0640, No Longer Enrolling: 10/18/2019
Locations: University of Colorado Hospital;
Protocol #18-2263, No Longer Enrolling: 10/22/2019
Locations: University of Colorado Hospital;
Protocol #18-2186, No Longer Enrolling: 11/28/2019
Locations: University of Colorado Hospital;
Protocol #18-2272, No Longer Enrolling: 11/28/2019
Locations: University of Colorado Hospital;
Protocol #18-2257, No Longer Enrolling: 11/28/2019
Locations: Childrens Hospital Colorado;
Protocol #18-2077, No Longer Enrolling: 11/28/2019
Locations: University of Colorado Hospital;
Protocol #18-2442, No Longer Enrolling: 11/28/2019
Locations: University of Colorado Cancer Center;
Protocol #18-2461, No Longer Enrolling: 11/28/2019
Locations: University of Colorado Hospital;
Protocol #18-2584, No Longer Enrolling: 11/28/2019
Locations: Rocky Mountain Regional VA Medical Center;
Protocol #18-2499, No Longer Enrolling: 10/28/2019
Locations: University of Colorado Hospital;
Protocol #18-2590, No Longer Enrolling: 11/28/2019
Locations: University of Colorado Hospital;
Protocol #18-2684, No Longer Enrolling: 8/4/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT00000000
Protocol #18-2701, No Longer Enrolling: 11/28/2019
Locations: University of Colorado Hospital;
Protocol #11-0674, No Longer Enrolling: 10/9/2021
Locations: Memorial Hospital Central, Memorial Hospital North;
Protocol #18-6128, No Longer Enrolling: 5/20/2020
Locations: Memorial Hospital Central;
Protocol #18-2699, No Longer Enrolling: 10/22/2019
Locations: University of Colorado Hospital;
Protocol #18-2828, No Longer Enrolling: 11/28/2019
Locations: University of Colorado Hospital;
Protocol #18-2840, No Longer Enrolling: 11/19/2019
Locations: University of Colorado Hospital;
To test wireless vital sign monitor in the field and determine feasibility.
Protocol #18-6102, No Longer Enrolling: 3/5/2021
Locations: Medical Center of the Rockies;
Protocol #18-2887, No Longer Enrolling: 10/30/2019
Locations: University of Colorado Hospital;
Protocol #19-0489, No Longer Enrolling: 4/19/2022
Locations: Barbara Davis Center, Outpatient CTRC, UCD Barbara Davis Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03875729
Protocol #19-0522, No Longer Enrolling: 10/23/2019
Locations: University of Colorado Hospital;
Protocol #14-1360, No Longer Enrolling: 10/9/2021
Locations: Childrens Hospital Colorado, University of Colorado Hospital;
Protocol #19-0693, No Longer Enrolling: 11/1/2019
Locations: University of Colorado Hospital;
Protocol #19-0653, No Longer Enrolling: 10/28/2019
Locations: University of Colorado Hospital;
Protocol #19-0950, No Longer Enrolling: 11/16/2019
Locations: University of Colorado Hospital;
Protocol #19-6064, No Longer Enrolling: 10/1/2019
Locations: Harmony Campus, Medical Center of the Rockies, Poudre Valley Hospital;
Protocol #19-0973, No Longer Enrolling: 11/1/2019
Locations: University of Colorado Hospital;
Protocol #19-1028, No Longer Enrolling: 12/28/2019
Locations: University of Colorado Hospital;
Protocol #19-1089, No Longer Enrolling: 11/7/2019
Locations: University of Colorado Hospital;
Protocol #19-1136, No Longer Enrolling: 11/7/2019
;
Protocol #13-2571, No Longer Enrolling: 10/1/2019
Locations: Childrens Hospital Colorado;
To test the predictive ability of the Trauma Sepcific Frailty Index.
Protocol #19-6084, No Longer Enrolling: 3/22/2022
Locations: Medical Center of the Rockies;
Protocol #19-1306, No Longer Enrolling: 10/22/2019
Locations: University of Colorado Hospital;
Protocol #19-1465, No Longer Enrolling: 10/31/2019
Locations: University of Colorado Hospital;
Protocol #19-1388, No Longer Enrolling: 10/1/2019
Locations: University of Colorado Hospital;
Protocol #13-2797, No Longer Enrolling: 10/4/2019
Locations: Childrens Hospital Colorado;
Protocol #19-1495, No Longer Enrolling: 10/1/2019
Locations: University of Colorado Hospital;
Protocol #15-0902, No Longer Enrolling: 7/8/2021
Locations: Childrens Hospital Colorado, Colorado Research Center;
Protocol #18-1461, No Longer Enrolling: 1/6/2021
Locations: University of Colorado Hospital;
Protocol #17-1414, No Longer Enrolling: 11/7/2019
Locations: Colorado Research Center;
Protocol #17-1411, No Longer Enrolling: 10/22/2019
Locations: University of Colorado Hospital;
Protocol #17-1591, No Longer Enrolling: 11/7/2019
Locations: University of Colorado Hospital;
Protocol #17-1378, No Longer Enrolling: 11/28/2019
Locations: University of Colorado Hospital;
Protocol #17-1401, No Longer Enrolling: 11/28/2019
Locations: Childrens Hospital Colorado;
Protocol #17-1798, No Longer Enrolling: 11/28/2019
Locations: University of Colorado Hospital;
Protocol #17-1733, No Longer Enrolling: 11/28/2019
Locations: University of Colorado Hospital;
Protocol #17-1942, No Longer Enrolling: 10/19/2019
Locations: University of Colorado Hospital;
Protocol #17-1794, No Longer Enrolling: 11/28/2019
Locations: University of Colorado Hospital;
Protocol #18-0119, No Longer Enrolling: 11/28/2019
Locations: University of Colorado Hospital;
Protocol #17-1753, No Longer Enrolling: 10/18/2019
Locations: University of Colorado Hospital;
Protocol #17-1763, No Longer Enrolling: 10/18/2019
Locations: University of Colorado Hospital;
Protocol #18-0079, No Longer Enrolling: 10/1/2019
Locations: Childrens Hospital Colorado;
Protocol #17-2115, No Longer Enrolling: 10/22/2019
Locations: University of Colorado Hospital;
Protocol #17-2116, No Longer Enrolling: 10/22/2019
Locations: University of Colorado Hospital;
Protocol #17-2167, No Longer Enrolling: 11/28/2019
Locations: University of Colorado Hospital;
Protocol #17-2142, No Longer Enrolling: 11/28/2019
Locations: Childrens Hospital Colorado;
Protocol #18-0080, No Longer Enrolling: 11/7/2019
Locations: University of Colorado Hospital;
Protocol #18-0023, No Longer Enrolling: 11/14/2019
Locations: University of Colorado Hospital;
Protocol #17-7788, No Longer Enrolling: 11/28/2019
Locations: University of Colorado Hospital;
Protocol #18-0081, No Longer Enrolling: 11/7/2019
Locations: University of Colorado Hospital;
Protocol #18-0094, No Longer Enrolling: 11/28/2019
Locations: University of Colorado Hospital;
Protocol #18-0201, No Longer Enrolling: 11/28/2019
Locations: Childrens Hospital Colorado, University of Colorado Hospital;
Protocol #18-0357, No Longer Enrolling: 11/7/2019
Locations: University of Colorado Hospital;
Protocol #18-0335, No Longer Enrolling: 11/28/2019
Locations: University of Colorado Hospital;
Protocol #18-0409, No Longer Enrolling: 10/22/2019
Locations: University of Colorado Hospital;
Protocol #18-0515, No Longer Enrolling: 11/28/2019
Locations: University of Colorado Hospital;
Protocol #18-0528, No Longer Enrolling: 11/28/2019
Locations: University of Colorado Hospital;
Protocol #18-0597, No Longer Enrolling: 10/18/2019
Locations: University of Colorado Hospital, University of Southern California;
Protocol #18-0636, No Longer Enrolling: 10/31/2019
Locations: University of Colorado Hospital;
Protocol #18-0596, No Longer Enrolling: 11/28/2019
Locations: University of Colorado Hospital;
Protocol #18-0749, No Longer Enrolling: 11/28/2019
;
Protocol #18-0263, No Longer Enrolling: 11/28/2019
Locations: University of Colorado Hospital;
Protocol #18-0717, No Longer Enrolling: 11/28/2019
Locations: University of Colorado Hospital;
Protocol #18-0726, No Longer Enrolling: 11/28/2019
Locations: University of Colorado Hospital;
Protocol #18-0748, No Longer Enrolling: 10/18/2019
Locations: University of Colorado Hospital;
Protocol #18-0598, No Longer Enrolling: 11/28/2019
Locations: Childrens Hospital Colorado;
Protocol #18-0776, No Longer Enrolling: 10/25/2019
Locations: University of Colorado Hospital;
Protocol #18-1383, No Longer Enrolling: 11/28/2019
Locations: Childrens Hospital Colorado;
Protocol #18-0848, No Longer Enrolling: 11/28/2019
Locations: University of Colorado Hospital;
Protocol #18-1420, No Longer Enrolling: 11/28/2019
Locations: Childrens Hospital Colorado;
Protocol #18-1278, No Longer Enrolling: 10/22/2019
Locations: University of Colorado Hospital;
Protocol #18-1277, No Longer Enrolling: 11/7/2019
Locations: University of Colorado Hospital;
Protocol #18-1453, No Longer Enrolling: 11/28/2019
Locations: University of Colorado Hospital;
Protocol #18-1720, No Longer Enrolling: 10/22/2019
Locations: University of Colorado Hospital;
Protocol #18-1732, No Longer Enrolling: 10/22/2019
Locations: University of Colorado Hospital;
Protocol #18-1708, No Longer Enrolling: 11/28/2019
Locations: University of Colorado Hospital;
Protocol #18-1943, No Longer Enrolling: 11/28/2019
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT03601442
Protocol #18-1898, No Longer Enrolling: 11/28/2019
Locations: University of Colorado Hospital;
Protocol #18-1815, No Longer Enrolling: 11/28/2019
Locations: Childrens Hospital Colorado;
Protocol #18-1634, No Longer Enrolling: 11/28/2019
Locations: University of Colorado Hospital;
Protocol #18-1987, No Longer Enrolling: 11/28/2019
Locations: University of Colorado Hospital;
Protocol #18-1861, No Longer Enrolling: 11/28/2019
Locations: University of Colorado Hospital;
Protocol #19-2297, No Longer Enrolling: 11/1/2019
Locations: Childrens Hospital Colorado;
Protocol #19-1132, No Longer Enrolling: 7/29/2021
Locations: Lone Tree Medical Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03989115
Protocol #19-1766, No Longer Enrolling: 10/22/2019
Locations: University of Colorado Hospital;
Protocol #19-1742, No Longer Enrolling: 12/24/2019
Locations: University of Colorado Hospital;
Protocol #19-1970, No Longer Enrolling: 10/22/2019
Locations: University of Colorado Hospital;
Protocol #18-1940, No Longer Enrolling: 11/1/2019
Locations: Childrens Hospital Colorado;
Protocol #19-0079, No Longer Enrolling: 5/14/2022
Locations: Childrens Hospital Colorado;
Protocol #19-2344, No Longer Enrolling: 12/7/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT00000000
The purpose of this study is to evaluate a heart pressure system called the CardioMEMS PA Sensor (referred to as "the device") in patients with heart failure. A small sensor is threaded through a vein into your heart on the tip of a catheter, and may allow your health care team to determine fluid balance in your body. The CardioMEMS HF System is FDA approved for a select group of patients. The study plans to see if it works in more patients. The study will also learn if using the device's data for other indicators of heart failure might reduce worsening heart failure resulting in visits to the hospital to treat heart failure or death. You may be eligible if you are at risk of having episodes of worsening heart failure.
Protocol #18-2129, No Longer Enrolling: 5/12/2022
Locations: Medical Center of the Rockies, Memorial Hospital Central, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT00531661
Protocol #19-0159, No Longer Enrolling: 8/15/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03614260
This is a Phase 2a, randomized, open-label, active control, multi-center study to assess the efficacy and safety of bleselumab in preventing the rFSGS in de novo kidney transplant subjects. Primary Objective: - To assess the efficacy of the bleselumab regimen (basiliximab induction, tacrolimus, steroids and bleselumab) compared with the SOC regimen (basiliximab induction, tacrolimus, steroids and MMF) in the prevention of the recurrence of focal segmental glomerulosclerosis (rFSGS) defined as nephrotic range proteinuria with proteincreatinine ratio (> or equal to 3.0 g/g) through 3 months post-transplant. Death, graft loss or lost to follow-up will be imputed as rFSGS. Secondary Objectives: - To assess the incidence of nephrotic range proteinuria with protein-creatinine ratio (> or equal to 3.0 g/g) through 6 and 12 months post-transplant. Death, graft loss or lost to follow-up will be imputed as rFSGS. - To assess the incidence of biopsy-proven acute rejection (BPAR, Banff Grade ≥ 1; local read) through 3, 6 and 12 months post-transplant. - To assess the incidence of efficacy failure defined as BPAR (Banff Grade ≥ 1; local read), death, graft loss or lost to follow-up through 12 months post-transplant. - To assess the incidence of biopsy-proven (blinded, central read) rFSGS through 3, 6 and 12 months post-transplant. - To assess the safety of the bleselumab regimen compared with the SOC regimen.
Protocol #17-1010, No Longer Enrolling: 10/10/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02921789
Our objective is to test the effect of breaking-up prolonged sitting with bouts of physical activity on metabolic flexibility, a recognized core component of metabolic health. Metabolic flexibility is defined as the body's ability to adapt fuel oxidation to changing fuel availability and energy demands.
Protocol #14-0429, No Longer Enrolling: 5/20/2021
Locations: CTRC-adult, University of Colorado Hospital;
Protocol #16-2436, No Longer Enrolling: 11/23/2019
Locations: University of Colorado Hospital;
Protocol #17-0321, No Longer Enrolling: 5/2/2020
Locations: University of Colorado Hospital;
Protocol #97-661, No Longer Enrolling: 9/24/2021
Locations: Outpatient CTRC, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT00005754
This study is designed to collect data for future investigation under the topic of perioperative care and variables affecting outcomes of dialysis access patients at UCHealth.
Protocol #17-1073, No Longer Enrolling: 8/18/2021
Locations: Department Specific Free Standing Clinic, University of Colorado Hospital;
This is a clinical trial of temozolomide that will be administered by mouth which is standard of care along with standard dose radiation therapy that is standard of care or with higher dose radiation therapy which is investigational.
Protocol #14-2131, No Longer Enrolling: 5/13/2022
Locations: Greeley Campus, Harmony Campus, Medical Center of the Rockies, Memorial Hospital Central, Memorial Hospital North, Poudre Valley Hospital;
More information available at ClinicalTrials.gov: NCT02179086
Protocol #16-0927, No Longer Enrolling: 8/16/2021
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02991144
Protocol #20-0292, No Longer Enrolling: 2/11/2020
Locations: University of Colorado Hospital;
Protocol #19-2412, No Longer Enrolling: 8/20/2021
Locations: Childrens Hospital Colorado;
Participants will be randomized into one of two treatment groups. In one treatment group, participants will receive the quadriceps tendon and patellar bone autograft. The second treatment group will received the all quadriceps tendon autograft. Both graft types are validated and widely used surgical approached in the pediatric and adolescent populations. We will follow participants for up to 5 years following their surgery. Participants' treatment will not differ from the normal standard of care treatment all patients receive, other than being randomized to a particular treatment group and completing questionnaires about pain and physical functioning periodically throughout treatment.
Protocol #19-1445, No Longer Enrolling: 2/28/2020
Locations: Childrens Hospital Colorado;
Protocol #20-0685, No Longer Enrolling: 5/21/2021
Locations: Childrens Hospital Colorado, Department Specific Free Standing Clinic, University of Colorado Hospital;
Protocol #19-1305, No Longer Enrolling: 4/9/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03665038
Protocol #19-2780, No Longer Enrolling: 10/20/2020
Locations: Greeley Campus, Harmony Campus, Medical Center of the Rockies, Memorial Hospital Central, Memorial Hospital North, Poudre Valley Hospital, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04034927
Protocol #19-2390, No Longer Enrolling: 2/4/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03974022
A randomized, double-blind study, placebo-controlled, multi-center, dose-ranging study in hospitalized patients with infected, non-draining pleural effusions. LTI-01 or placebo will be administered through the vein once daily for up to 3 days to facilitate pleural (lung) fluid draining.
Protocol #20-0436, No Longer Enrolling: 9/25/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04234919
To identify genetic and circulating biomarkers of severe bleeding and predictors of brain outcomes in HHT patients. Patients will be evaluated about every 18 months for up to 10 years
Protocol #20-0039, No Longer Enrolling: 6/2/2020
Locations: University of Colorado Hospital;
Protocol #19-1759, No Longer Enrolling: 8/12/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04077099
Protocol #19-0123, No Longer Enrolling: 6/29/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT00000000
Protocol #19-0181, No Longer Enrolling: 6/5/2020
Locations: University of Colorado Hospital;
Protocol #19-0779, No Longer Enrolling: 6/5/2020
;
Protocol #19-0922, No Longer Enrolling: 6/5/2020
Locations: Childrens Hospital Colorado;
Protocol #19-0596, No Longer Enrolling: 6/5/2020
Locations: Childrens Hospital Colorado;
Protocol #19-1407, No Longer Enrolling: 6/5/2020
;
Protocol #19-1512, No Longer Enrolling: 6/5/2020
Locations: University of Colorado Hospital;
Protocol #19-1517, No Longer Enrolling: 6/5/2020
Locations: University of Colorado Hospital;
Protocol #19-1568, No Longer Enrolling: 6/5/2020
Locations: University of Colorado Hospital;
Protocol #17-2279, No Longer Enrolling: 6/5/2020
Locations: University of Colorado Hospital;
Protocol #19-1799, No Longer Enrolling: 6/5/2020
Locations: University of Colorado Hospital;
Protocol #20-0202, No Longer Enrolling: 6/5/2020
Locations: Denver Health Medical Center;
Protocol #20-1197, No Longer Enrolling: 1/4/2022
Locations: Barbara Davis Center, Childrens Hospital Colorado, University of Colorado Hospital;
Protocol #20-0232, No Longer Enrolling: 7/14/2020
Locations: University of Colorado Hospital;
Protocol #20-1325, No Longer Enrolling: 7/16/2020
Locations: University of Colorado Hospital;
Protocol #20-0560, No Longer Enrolling: 7/7/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04469478
Protocol #19-2873, No Longer Enrolling: 7/23/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04136184
This is a clinical trial investigating the effects of the following different radiation and drug pairings of which the patient will be randomly assigned: Radiation therapy and Cisplatin(Standard of Care), Radiation therapy and Cisplatin(Investigational treatment) or Radiation therapy and Docetaxel/ Cetuximab(Investigational treatment)
Protocol #14-1299, No Longer Enrolling: 2/18/2021
Locations: Lone Tree Medical Center, Memorial Hospital Central, Memorial Hospital North, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT01810913
Protocol #20-0405, No Longer Enrolling: 8/5/2020
Locations: University of Colorado Hospital;
Protocol #19-1560, No Longer Enrolling: 8/18/2020
Locations: University of Colorado Hospital;
This is a mult-center trial where up to 200 pediatric patients will be enrolled. pediatric patients who have a gastrostomy tube placed will be eligible for enrollment and will be randomized to either receive the standard of care tic-tac-toe dressing or the new Button Huggie gastrostomy tube securement device. The patients will be followed at 4, 8, and 12 weeks after placement of the device or dressing to determine satisfaction with the device as well as post-operative outcomes.
Protocol #18-1615, No Longer Enrolling: 9/18/2020
Locations: Childrens Hospital Colorado, Childrens Hospital Colorado at Memorial;
Protocol #20-1737, No Longer Enrolling: 3/18/2021
Locations: Greeley Campus, Harmony Campus, Highlands Ranch Hospital, Medical Center of the Rockies, Poudre Valley Hospital;
More information available at ClinicalTrials.gov: NCT04310007
Protocol #20-0091, No Longer Enrolling: 10/10/2020
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT01694953
There will be at least 7 study visits, over 2 years. If symptoms develop visits will be more frequent
Protocol #20-2078, No Longer Enrolling: 10/16/2020
Locations: Anschutz Health and Wellness, Barbara Davis Center, Childrens Hospital Colorado, Renal Research Center;
More information available at ClinicalTrials.gov: NCT04505722
Protocol #20-2505, No Longer Enrolling: 2/13/2021
Locations: Childrens Hospital Colorado;
Protocol #20-1227, No Longer Enrolling: 1/8/2022
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04372628
Protocol #15-150, No Longer Enrolling: 12/1/2020
Locations: Childrens Hospital Colorado;
Protocol #20-2809, No Longer Enrolling: 12/11/2020
Locations: University of Colorado Hospital;
Protocol #20-2972, No Longer Enrolling: 5/12/2022
Locations: Outpatient CTRC, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04655586
Protocol #20-0490, No Longer Enrolling: 8/18/2021
Locations: Childrens Hospital Colorado;
Protocol #20-3119, No Longer Enrolling: 1/13/2021
Locations: University of Colorado Hospital;
Protocol #20-2220, No Longer Enrolling: 6/6/2021
Locations: Barbara Davis Center;
Protocol #20-1000, No Longer Enrolling: 3/19/2021
Locations: Brain Imaging Center (BIC), University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04495556
Protocol #21-2658, No Longer Enrolling: 3/19/2021
Locations: University of Colorado Hospital;
Protocol #17-6100, No Longer Enrolling: 11/20/2021
;
Protocol #17-0396, No Longer Enrolling: 4/30/2021
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02959944
Protocol #20-2130, No Longer Enrolling: 3/23/2021
Locations: University of Colorado Hospital;
Protocol #20-1361, No Longer Enrolling: 3/29/2021
Locations: University of Colorado Hospital;
Protocol #20-2979, No Longer Enrolling: 3/29/2021
Locations: University of Colorado Hospital;
Protocol #20-2222, No Longer Enrolling: 11/19/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04619004
To determine the safety and efficacy of Pfizer COVID-19 vaccine in the pregnant population.
Protocol #21-2608, No Longer Enrolling: 4/9/2021
Locations: Childrens Hospital Colorado, UCHealth Internal Medical Clinic - Lowry, University of Colorado Hospital;
Protocol #20-2689, No Longer Enrolling: 5/4/2022
Locations: Greeley Campus, Medical Center of the Rockies, Poudre Valley Hospital, Yampa Valley Medical Center;
Protocol #20-2302, No Longer Enrolling: 12/29/2021
Locations: Childrens Hospital Colorado, University of Colorado Hospital;
Protocol #20-6083, No Longer Enrolling: 4/7/2022
Locations: Medical Center of the Rockies;
Protocol #21-3684, No Longer Enrolling: 9/22/2021
Locations: Long's Peak Hospital;
Protocol #21-2771, No Longer Enrolling: 1/22/2022
Locations: Medical Center of the Rockies;
More information available at ClinicalTrials.gov: NCT04198701
Protocol #20-1739, No Longer Enrolling: 8/25/2021
Locations: University of Colorado Hospital;
Protocol #21-2951, No Longer Enrolling: 4/20/2022
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04793958
Protocol #21-3644, No Longer Enrolling: 9/22/2021
Locations: University of Colorado Hospital;
Protocol #18-1272, No Longer Enrolling: 10/5/2021
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02730299
Protocol #21-3829, No Longer Enrolling: 2/11/2022
Locations: Childrens Hospital Colorado;
Protocol #21-3050, No Longer Enrolling: 2/24/2022
Locations: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT04994002
Protocol #21-4007, No Longer Enrolling: 2/16/2022
Locations: Childrens Hospital Colorado;
Good sleep is important for good health. This research study will test a guided breathing experience to see if it can help people relax and fall asleep more easily.
Protocol #21-3977, No Longer Enrolling: 3/22/2022
Locations: Department Specific Free Standing Clinic;
Protocol #21-3969, No Longer Enrolling: 1/20/2022
Locations: Comprehensive Women's Health Center, Outpatient CTRC;
Protocol #21-4539, No Longer Enrolling: 2/16/2022
Locations: University of Colorado Hospital;
Protocol #22-0434, No Longer Enrolling: 5/10/2022
Locations: University of Colorado Hospital;
Primary Objective: To evaluate the effectiveness of an 8-week, group-based, Acceptance and Commitment Therapy (ACT) intervention for chronic pain management in cancer survivors who have completed active treatment. Secondary Objective: To evaluate the implementation of an 8-week, group-based, ACT intervention for chronic pain management in cancer survivors who have completed active treatment.
Protocol #18-1102, No Longer Enrolling: 11/12/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03661840
A multicenter, placebo-controlled, randomized, dose escalation, safety, and tolerability study of UNEX-42 in infants born at <27 weeks of GA at high risk for BPD
Protocol #18-2881, No Longer Enrolling: 3/31/2021
Locations: Childrens Hospital Colorado, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03857841
Protocol #19-0382, No Longer Enrolling: 4/3/2020
Locations: Childrens Hospital Colorado;
Protocol #16-0994, No Longer Enrolling: 4/28/2022
Locations: Childrens Hospital Colorado;
This study is a multi-country, multicenter, observational, prospective, longitudinal cohort study which will include patients with a physician diagnosis, or suspected diagnosis, of asthma and/or COPD. Patients will undergo clinical assessments and receive standard medical care as determined by the treating physician. All patients enrolled in the NOVELTY study will be followed up yearly by their treating physician for a total duration of three years. In addition, patients are expected to be followed up remotely once every quarter.
Protocol #17-0706, No Longer Enrolling: 12/21/2019
Locations: University of Colorado Hospital;
Protocol #17-0868, No Longer Enrolling: 9/28/2021
Locations: University of Colorado Hospital;
This study plans to learn more about the safety and tolerability of inhaled N-Acetylcysteine (NAC) in patients with pulmonary fibrosis. We will also create a bank of data, blood, and sputum from IPF patients for future research. NAC is a medication used to loosen thick mucus. NAC was initially licensed for use in 1968. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system, and it is available as a generic medication and is not very expensive. Inhaled NAC has been used as a mucus-dissolving therapy in respiratory conditions with excessive and/or thick mucus production.
Protocol #17-1477, No Longer Enrolling: 6/30/2021
Locations: Outpatient CTRC, University of Colorado Hospital;
GSK is currently developing a once-daily ?closed? triple therapy of an ICS/LAMA/LABA combination [FF/UMEC/Vilanterol (VI)] in a single device, with the aim of providing a new treatment option for the management of asthma by improving lung function, health-related quality of life (HRQoL) and symptom control over established combination therapies. Through the comparison of a closed triple therapy to a standard of care ICS/LABA combination therapy this study will provide important information to prescribers regarding the benefit of step-up to closed triple therapy to patients uncontrolled on ICS/LABA.
Protocol #17-2041, No Longer Enrolling: 5/25/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02924688
This is a 24 week study to evaluate the safety of using oral treprostinil to treat PH associated with HFpEF
Protocol #17-0163, No Longer Enrolling: 12/3/2019
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03037580
This is an open-label, multicenter study designed to evaluate the efficacy and safety of reducing oral corticosteroid (OCS) use after initiation of a 30 mg dose of benralizumab administered subcutaneously (SC) every 4 weeks (Q4W) up until the third dose of benralizumab and then every 8 weeks (Q8W) thereafter in patients with severe eosinophilic asthma who are receiving high-dose inhaled corticosteroids (ICS)/long-acting β2 agonists (LABAs) and OCS with or without additional asthma controller(s). After they sign the informed consent form, patients will undergo a screening visit (Visit 1) to assess eligibility criteria and laboratory tests. All patients who are not already taking prednisone/prednisolone as their OCS treatment will be switched to prednisone/prednisolone, and the laboratory tests will be delayed 3 to 7 days. Patients still fulfilling inclusion/ sion criteria at Visit 2 (Week 0) will enter the study and receive open-label benralizumab.
Protocol #18-1978, No Longer Enrolling: 5/4/2022
Locations: Outpatient CTRC, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03557307
Protocol #18-2482, No Longer Enrolling: 1/6/2021
Locations: University of Colorado Hospital;
Protocol #18-2534, No Longer Enrolling: 5/4/2022
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03711162
Protocol #19-2946, No Longer Enrolling: 12/2/2020
Locations: University of Colorado Hospital;
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis
Protocol #18-1624, No Longer Enrolling: 12/9/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03568318
A Phase 2, multicenter, randomized, placebo-controlled, double-blind, parallel-group study for subjects with moderate to severe AD whose disease cannot be adequately controlled with topical medications or for whom topical treatment is medically inadvisable.
Protocol #19-0144, No Longer Enrolling: 2/18/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03703102
This study is designed to test the effectiveness of the oral drug Apremilast in patients with mild to moderate Plaque Psoriasis. The study lasts ~36 weeks (around 9 months) from start to finish for each participant. There are around 11 scheduled visits throughout the 36 weeks that participants are asked to come to the clinic to see the research team. There are treatment groups and a placebo group in this study. After the first 16 weeks of the study, everyone from the placebo group will be placed into one of the treatment groups. Please direct any further questions or inquries to the Dermatology Clinical Research Team @ 720-848-0556 or diane.ladell@cuanschutz.edu OR daniel.uy@cuanschutz.edu
Protocol #18-2578, No Longer Enrolling: 5/2/2020
Locations: University of Colorado Hospital;
Protocol #18-1380, No Longer Enrolling: 6/3/2021
Locations: Childrens Hospital Colorado;
Protocol #18-2798, No Longer Enrolling: 2/13/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03732807
Study B7981032 will investigate PF-06651600 in participants with AA. This is a Phase 3, open-label, multi-center, long-term study designed to evaluate the safety and efficacy of PF-06651600 in adults and adolescents 12 years of age. The study will have a maximum duration of approximately 26 months. This includes up to a 5-week screening period, a 24-month open-label treatment period, and a 4-week follow-up period (See Schema). Eligible participants will be given the opportunity to enroll from the index studies B7931005 and B7981015, as well as de novo participants (ie, those who have not previously received study intervention in Study B7931005 or B7981015).
Protocol #19-2839, No Longer Enrolling: 2/13/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04006457
Protocol #20-1938, No Longer Enrolling: 4/28/2022
Locations: Childrens Hospital Colorado;
Protocol #20-2721, No Longer Enrolling: 4/20/2022
Locations: Outpatient CTRC, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04598477
Protocol #20-3053, No Longer Enrolling: 7/14/2021
Locations: Outpatient CTRC, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04811131
The study will be a prospective, multi-center, non-randomized, single-arm clinical study to evaluate the effectiveness of SpinalStim.
Protocol #17-1037, No Longer Enrolling: 8/25/2020
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03176303
Protocol #18-6071, No Longer Enrolling: 10/2/2019
Locations: Memorial Hospital Central, Memorial Hospital North;
More information available at ClinicalTrials.gov: NCT02469857
Protocol #18-2513, No Longer Enrolling: 10/9/2021
Locations: Childrens Hospital Colorado;
Primary Objective: Assess whether parental rating of problems on the Attention and Social Withdrawal indices of the Child Behavior Checklist at 4 years of age for children of mothers who received prenatal phosphatidylcholine supplementation are lower, compared to children whose mothers received placebo.
Protocol #16-1510, No Longer Enrolling: 12/3/2021
Locations: Colorado Research Center, Denver Health Medical Center, Department Specific Free Standing Clinic, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03028857
Protocol #17-1047, No Longer Enrolling: 8/18/2021
Locations: Comprehensive Women's Health Center, Comprehensive Womens Health Center, University of Colorado Hospital;
Protocol #18-0226, No Longer Enrolling: 11/14/2020
Locations: Comprehensive Women's Health Center, Comprehensive Womens Health Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03432416
Protocol #17-2186, No Longer Enrolling: 5/4/2022
Locations: Outpatient CTRC, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02938923
Protocol #18-0803, No Longer Enrolling: 6/10/2021
Locations: Childrens Hospital Colorado, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03717935
A randomized, single-blind, phase IIb/III controlled clinical trial to measure contraceptive efficacy of Mona Lisa NT Cu380 Mini. To measure contraceptive efficacy of the test product
Protocol #17-0225, No Longer Enrolling: 8/18/2021
Locations: Comprehensive Women's Health Center, Comprehensive Womens Health Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03124160
The primary objective of this study is: To determine the efficacy of maternal immunization with the RSV F vaccine against medically-significant RSV lower respiratory tract infection (LRTI) with EITHER hypoxemia (peripheral oxygen saturation [SpO2] < 95% at sea level or < 92% at altitudes > 1800 meters) OR tachypnea (≥ 70 bpm for infants 0 to 59 days of age or ≥ 60 bpm for infants ≥ 60 days of age) through the first 90 days of life in infants of maternal RSV F vaccinees as compared to placebo recipients. In the event that efficacy is shown through the first 90 days of life, a hierarchical sequence of hypothesis tests will be carried out to examine efficacy at 120, 150, and 180 days of life.
Protocol #18-1121, No Longer Enrolling: 1/6/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02624947
The study is a multicenter, open-label, evaluation of the efficacy and safety of LNG20 IUS for treatment of heavy menstrual bleeding. Primary objective: Assess the efficacy of a levonorgestrel 52 mg intrauterine system (LNG20 IUS) as a treatment for heavy menstrual bleeding. Secondary objectives: Assess safety, tolerability, bleeding patterns, and continuation rates of LNG20 IUS in women using LNG20 IUS for heavy menstrual bleeding.
Protocol #18-2249, No Longer Enrolling: 8/18/2021
Locations: Comprehensive Women's Health Center, Comprehensive Womens Health Center, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03642210
Cepheid is developing a rapid molecular diagnostic test for the detection of Group B Strep (GBS), a bacterial infection associated with serious illness in newborns born to women who are have a GBS infection. This study will collect specimens from pregnant women for the development of a prototype assay (laboratory test).
Protocol #18-2283, No Longer Enrolling: 10/17/2019
Locations: University of Colorado Hospital;
Protocol #15-1141, No Longer Enrolling: 9/12/2020
Locations: Childrens Hospital Colorado;
? 1 in person visit and up to 3 short phone visits over a 1 month period ? Vital signs, blood draw, urine pregnancy test ? Daily diary card completion
Protocol #18-0841, No Longer Enrolling: 1/11/2022
Locations: Childrens Hospital Colorado, Comprehensive Women's Health Center, Comprehensive Womens Health Center;
If you join the study, you will participate in two study sessions, which can be completed either in-person (at Anschutz Medical Campus, in Aurora, CO) or remotely - over the internet, over the course of 2 months. The first part of the study is the screening session. During this session, the research staff will conduct an interview with you and complete questionnaires about your medical and mental health history, and your mood. The second and last part of the study is the test session. During this session, you will complete surveys about your mood, and you will rate 160 digital images. Forty of those images will be pleasant, 40 will be unpleasant, 40 will be neutral, and 40 will be erotic. You will rate these images on scales of how pleasant/unpleasant and of how arousing/non-arousing you find these images. To investigate ratings of digital images across the female menstrual cycle
Protocol #19-2872, No Longer Enrolling: 1/20/2021
Locations: Department Specific Free Standing Clinic, University of Colorado, Boulder;
Protocol #20-0189, No Longer Enrolling: 3/23/2021
Locations: Childrens Hospital Colorado;
Protocol #19-2795, No Longer Enrolling: 12/17/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04042116
Protocol #20-0589, No Longer Enrolling: 5/4/2022
Locations: Outpatient CTRC, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03617263
Protocol #20-1524, No Longer Enrolling: 10/13/2021
Locations: Outpatient CTRC, University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03319628
Protocol #20-1409, No Longer Enrolling: 10/30/2021
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04590248
Protocol #21-4187, No Longer Enrolling: 1/8/2022
Locations: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03587311